UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q


	☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2020~~ 2021

◻

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 1-33818

RESHAPE LIFESCIENCES INC.

(Exact name of registrant as specified in its charter)

Delaware	48-1293684
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

1001 Calle Amanecer, San Clemente, California 92673
(Address of principal executive offices, including zip code)

(949) 429-6680
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol	Name of Each Exchange on which Registered
Common stock, $0.001 par value per share		RSLS	OTCQB Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated Filer	☐
Non-accelerated filer	☒	Smaller Reporting Company	☒
Emerging Growth Company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November~~May 1114, ~~2020~~2021, 56,~~586~~166,554 shares of the registrant’s Common Stock were outstanding.

Table of Contents

INDEX


PART I – FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements (unaudited)	3
	Condensed Consolidated Balance Sheets at ~~September~~March 3031, ~~2020~~2021 and December 31, ~~2019~~2020	3
	Condensed Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020	4
	Condensed Consolidated Statements of Comprehensive Loss for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020	5
	Condensed Consolidated Statements of Stockholders’ Equity for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020	6
	Condensed Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020	87
	Notes to Condensed Consolidated Financial Statements	98
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1918
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2824
Item 4.	Controls and Procedures	2824

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	2825
Item 1A.	Risk Factors	2925
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2925
Item 3.	Defaults Upon Senior Securities	2925
Item 4.	Mine Safety Disclosures	2925
Item 5.	Other Information	2925
Item 6.	Exhibits	3026
SIGNATURES		3127

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Balance Sheets

(dollars in thousands, except per share amounts; unaudited)


	~~September~~March 3031,		December 31,
	~~2020~~2021		~~2019~~2020
ASSETS
Current assets:
Cash and cash equivalents	$	~~1,857~~896	$	2,~~935~~957
Restricted cash		501,050		50
Accounts and other receivables (net of allowance for doubtful accounts of $893 and $709 respectively)		2,951		4,096
Accounts and other receivables (net of allowance for doubtful accounts of $442 and $968 respectively)		3,373		2,620
Inventory (Note 3)		1,988		1,317
Inventory		2,095		2,244
Prepaid expenses and other current assets (Note 3)		1,304		1,711
Prepaid expenses and other current assets		836		1,073
Total current assets		8,~~150~~250		108,~~109~~944
Property and equipment, net		~~431~~718		16584
Operating lease right-of-use assets (Note 6)		540		758
Operating lease right-of-use assets		390		465
Other intangible assets, net		2726,~~424~~612		2827,~~674~~022
Other assets		46		9946
Total assets	$	36,~~591~~016	$	3937,~~656~~061
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	3,~~761~~637	$	43,~~263~~655
Accrued and other liabilities (Note 3)		3,257		3,821
Accrued and other liabilities		4,017		3,630
Warranty liability, current		~~383~~390		~~105~~397
Debt, current portion, net of deferred financing costs		613,~~558~~268		13,~~909~~609
Operating lease liabilities, current (Note 6)		309		291
Operating lease liabilities, current		320		314
Total current liabilities		1421,~~268~~632		1011,~~389~~605
Debt, noncurrent portion		~~3,204~~—		29,~~728~~168
Operating lease liabilities, noncurrent (Note 6)		243		477
Operating lease liabilities, noncurrent		82		163
Warranty liability, noncurrent		~~1,091~~979		1,~~253~~022
Deferred income taxes		~~702~~615		~~702~~615
Total liabilities		1923,~~508~~308		1522,~~549~~573
Commitments, contingencies (Note 12)
Commitments, contingencies and subsequent events
Stockholders’ equity:
Preferred stock, 5,000,000 shares authorized:
Series B convertible preferred stock, $0.001 par value; 3 issued and outstanding at September 30, 2020 and December 31, 2019, respectively		—		—
Series B convertible preferred stock, $0.001 par value; 3 issued and outstanding at March 31, 2021 and December 31, 2020, respectively		—		—
Series C convertible preferred stock, $0.001 par value; 95,388 shares issued and outstanding at September 30, 2020 and December 31, 2019		1		1
Series C convertible preferred stock, $0.001 par value; 95,388 shares issued and outstanding at March 31, 2021 and December 31, 2020		1		1
Common stock, $0.001 par value; 275,000,000 shares authorized at September 30, 2020 and December 31, 2019; 5,586,554 and 391,739 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		5		—
Common stock, $0.001 par value; 275,000,000 shares authorized at March 31, 2021 and December 31, 2020; 6,166,554 shares issued and outstanding at both March 31, 2021 and December 31, 2020		6		6
Additional paid-in capital		~~523~~532,~~442~~504		~~517~~529,~~311~~429
Accumulated deficit		(~~506~~519,~~291~~701)		(~~493~~514,~~197~~827)
Accumulated other comprehensive loss		(74102)		(8121)
Total stockholders’ equity		1712,~~083~~708		2414,~~107~~488
Total liabilities and stockholders’ equity	$	36,~~591~~016	$	3937,~~656~~061

See accompanying notes to Condensed Consolidated Financial Statements.

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Operations

(dollars in thousands, except per share amounts; unaudited)


	Three Months Ended ~~September~~March 3031,				~~Nine Months Ended September 30,~~
		~~2020~~2021		~~2019~~2020		~~2020~~		~~2019~~
Revenue	$	3,~~602~~221	$	32,~~515~~789	$	~~8,092~~	$	~~11,039~~
Cost of revenue		~~1,321~~937		1,~~413~~285		~~3,471~~		~~3,849~~
Gross profit		2,~~281~~284		21,~~102~~504		~~4,621~~		~~7,190~~
Operating expenses:
Sales and marketing		1,~~160~~250		~~950~~1,454		~~3,446~~		~~3,338~~
General and administrative		2,~~434~~720		42,~~412~~836		~~7,809~~		~~14,237~~
Research and development		~~859~~571		~~858~~1,295		~~2,619~~		~~2,874~~
Impairment of intangible assets		—		—		—		6,588
Total operating expenses		4,541		5,585
Loss on litigation settlement		—		1,500		—		1,500
Operating loss		(2,257)		(4,081)
Total operating expenses		4,453		7,720		13,874		28,537
Other expense (income), net:
Operating loss		(2,172)		(5,618)		(9,253)		(21,347)
Interest expense, net		599		104
Other expense (income), net:
Loss on extinguishment of debt, net		1,960		—
Interest expense, net		739		74		1,632		390
Loss on foreign currency exchange		33		144
Loss on extinguishment of debt		2,435		—		2,435		71
Loss before income tax provision		(4,849)		(4,329)
Warrant expense		—		22,564		—		26,821
Income tax expense (benefit)		25		(18)
Gain on foreign currency exchange		(128)		(229)		(118)		(229)
Net loss	$	(4,874)	$	(4,311)
Other, net		—		727		—		1,336
Net loss per share - basic and diluted:
Loss before income tax provision		(5,218)		(28,754)		(13,202)		(49,736)
Net loss per share - basic and diluted	$	(0.70)	$	(0.63)
Income tax benefit		(39)		—		(108)		(586)
Shares used to compute basic and diluted net loss per share		6,968,221		6,859,240
Net loss attributable to common shareholders	$	(5,179)	$	(28,754)	$	(13,094)	$	(49,150)
Net loss per share - basic and diluted:
Net loss per share - basic and diluted	$	(0.74)	$	(106.44)	$	(1.89)	$	(235.42)
Shares used to compute basic and diluted net loss per share		6,968,221		270,136		6,913,188		208,777

See accompanying notes to Condensed Consolidated Financial Statements.

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Comprehensive Loss

(dollars in thousands; unaudited)


	Three Months Ended ~~September~~March 3031,				~~Nine Months Ended September 30,~~
	2021	~~2020~~	~~2019~~2020		~~2020~~		~~2019~~
Net loss	$	(54,~~179~~874)	$	(284,~~754~~311)	$	~~(13,094)~~	$	~~(49,150)~~
Foreign currency translation adjustments		~~(45)~~19		(948)		~~(66)~~		~~(9)~~
Other comprehensive loss, net of tax		(45)		(9)		(66)		(9)
Other comprehensive income (loss), net of tax		19		(48)
Comprehensive loss	$	(54,~~224~~855)	$	(284,~~763~~359)	$	~~(13,160)~~	$	~~(49,159)~~

See accompanying notes to Condensed Consolidated Financial Statements.

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Stockholders’ Equity

(dollars in thousands; unaudited)


	Three Months Ended September 30, 2020
	Series B Convertible			Series C Convertible						Additional				Accumulated Other		Total
	Preferred Stock			Preferred Stock			Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Income (Loss)		Equity
Balance June 30, 2020	3	$	—	95,388	$	1	5,586,554	$	5	$	520,288	$	(501,112)	$	(29)	$	19,153
Net loss	—		—	—		—	—		—		—		(5,179)		—		(5,179)
Other comprehensive loss, net of tax	—		—	—		—	—		—		—		—		(45)		(45)
Stock-based compensation expense	—		—	—		—	—		—		255		—		—		255
Issuance of warrants	—		—	—		—	—		—		2,899		—		—		2,899
Institutional exercise of warrants	—		—	—		—	—		—		—		—		—		—
Cashless exercise of warrants	—		—	—		—	—		—		—		—		—		—
Common stock issued for professional services	—		—	—		—	—		—		—		—		—		—
Balance September 30, 2020	3	$	—	95,388	$	1	5,586,554	$	5	$	523,442	$	(506,291)	$	(74)	$	17,083


	~~Nine~~Three Months Ended ~~September~~March 3031, ~~2020~~2021
	Series B Convertible			Series C Convertible						Additional				Accumulated Other		Total
	Preferred Stock			Preferred Stock			Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		~~Income (~~Loss)		Equity
Balance December 31, 2019	3	$	—	95,388	$	1	391,739	$	—	$	517,311	$	(493,197)	$	(8)	$	24,107
Balance December 31, 2020	3	$	—	95,388	$	1	6,166,554	$	6	$	529,429	$	(514,827)	$	(121)	$	14,488
Net loss	—		—	—		—	—		—		—		(134,~~094~~874)		—		(134,~~094~~874)
Other comprehensive income (loss), net of tax	—		—	—		—	—		—		—		—		(66)		(66)
Other comprehensive income, net of tax	—		—	—		—	—		—		—		—		19		19
Stock-based compensation expense	—		—	—		—	—		—		~~1,029~~101		—		—		~~1,029~~101
Issuance of warrants	—		—	—		—	—		—		42,~~292~~974		—		—		42,~~292~~974
Institutional exercise of warrants	—		—	—		—	5,085,834		5		605		—		—		610
Balance March 31, 2021	3	$	—	95,388	$	1	6,166,554	$	6	$	532,504	$	(519,701)	$	(102)	$	12,708
Cashless exercise of warrants	—		—	—		—	58,981		—		—		—		—		—
Common stock issued for professional services	—		—	—		—	50,000		—		205		—		—		205
Balance September 30, 2020	3	$	—	95,388	$	1	5,586,554	$	5	$	523,442	$	(506,291)	$	(74)	$	17,083

See accompanying notes to Condensed Consolidated Financial Statements.


	Three Months Ended March 31, 2020
	Series B Convertible			Series C Convertible						Additional				Accumulated Other		Total
	Preferred Stock			Preferred Stock			Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Loss		Equity
Balance December 31, 2019	3	$	—	95,388	$	1	391,739	$	—	$	517,311	$	(493,197)	$	(8)	$	24,107
Net loss	—		—	—		—	—		—		—		(4,311)		—		(4,311)
Other comprehensive loss, net of tax	—		—	—		—	—		—		—		—		(48)		(48)
Stock-based compensation expense	—		—	—		—	—		—		427		—		—		427
Issuance of warrants	—		—	—		—	—		—		1,393		—		—		1,393
Balance March 31, 2020	3	$	—	95,388	$	1	391,739	$	—	$	519,131	$	(497,508)	$	(56)	$	21,568

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Stockholders’ Equity (Continued)

(dollars in thousands; unaudited)


	Three Months Ended September 30, 2019
	Series B Convertible			Series C Convertible			Series E Convertible						Additional				Accumulated		Total
	Preferred Stock			Preferred Stock			Preferred Stock			Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Income (Loss)		Equity
Balance June 30, 2019	3	$	—	95,388	$	1	—	$	—	237,544	$	—	$	452,777	$	(439,386)	$	—	$	13,392
Net loss	—		—	—		—	—		—	—		—		—		(28,754)		—		(28,754)
Other comprehensive income (loss), net of tax	—		—	—		—	—		—	—		—		—		—		(9)		(9)
Stock-based compensation expense	—		—	—		—	—		—	—		—		(497)		—		—		(497)
Institutional sales of common stock and warrants, net of issuance costs	—		—	—		—	—		—	69,167		—		150		—		—		150
Issuance of common stock upon exercise of warrants	—		—	—		—	—		—	47,083		—		56		—		—		56
Balance September 30, 2019	3	$	—	95,388	$	1	—	$	—	353,794	$	—	$	452,486	$	(468,140)	$	(9)	$	(15,662)


	Nine Months Ended September 30, 2019
	Series B Convertible			Series C Convertible			Series E Convertible						Additional				Accumulated		Total
	Preferred Stock			Preferred Stock			Preferred Stock			Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Income (Loss)		Equity
Balance December 31, 2018	159	$	—	95,388	$	1	—	$	—	73,092	$	—	$	450,652	$	(418,990)	$	—	$	31,663
Net loss	—		—	—		—				—		—		—		(49,150)		—		(49,150)
Other comprehensive income (loss), net of tax	—		—	—		—	—		—	—		—		—		—		(9)		(9)
Stock-based compensation expense	—		—	—		—	—		—	—		—		1,486		—		—		1,486
Warrant expense	—		—	—		—	—		—	—		—		131		—		—		131
Institutional sales of common stock and warrants, net of issuance costs	—		—	—		—	—		—	200,202		—		478		—		—		478
Warrant adjustment	—		—	—		—	—		—	—		—		(312)		—		—		(312)
Conversion of common stock into convertible preferred stock	—		—	—		—	1,192,000		12	(9,933)		—		(12)		—		—		—
Conversions of convertible preferred stock into common stock	(156)		—	—		—	(1,192,000)		(12)	9,933		—		12		—		—		—
Issuance of common stock upon exercise of warrants, net of issuance costs	—		—	—		—	—		—	80,500		—		51		—		—		51
Balance September 30, 2019	3	$	—	95,388	$	1	—	$	—	353,794	$	—	$	452,486	$	(468,140)	$	(9)	$	(15,662)

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Cash Flows

(dollars in thousands; unaudited)


	~~Nine~~Three Months Ended ~~September~~March 3031,
	~~2020~~2021		~~2019~~2020
Cash flows from operating activities:
Net loss	$	(134,~~094~~874)	$	(494,~~150~~311)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		87		364
Amortization of intangible assets		~~1,249~~411		~~1,249~~417
Impairment of intangible assets		—		6,588
Noncash interest expense		43		58
Noncash interest expense		175		880
Loss on extinguishment of debt, net		1,960		—
Fair value adjustment to embedded derivative		—		(481)
Stock-based compensation		101		427
Loss on extinguishment of debt		2,435		71
Bad debt expense		27		149
Stock-based compensation		1,029		1,486
Provision for inventory excess and obsolescence		1		—
Bad debt expense		184		287
Amortization of debt discount and deferred debt issuance costs		461		47
Provision for inventory excess and obsolescence		244		—
Other noncash items		17		18
Warrant expense		—		26,821
Amortization of debt discount and deferred debt issuance costs		1,392		—
Deferred income tax benefit		—		(586)
Other noncash items		21		31
Change in operating assets and liabilities:
Accounts and other receivables		~~962~~(780)		~~(2,343)~~848
Inventory		~~(915)~~182		~~(204)~~60
Prepaid expenses and other current assets		~~613~~237		(~~527~~274)
Accounts payable and accrued liabilities		~~(1,260)~~296		~~2,986~~(865)
Warranty liability		~~116~~(50)		—173
Other		53—		~~(23)~~4
Net cash used in operating activities		(61,~~788~~961)		(123,~~879~~245)
Cash flows from investing activities:
Capital expenditures		(~~230~~119)		—
Cash used in investing activities:		(~~230~~119)		—
Cash flows from financing activities:
Proceeds from issuance of subordinated convertible debentures		—		2,000
Proceeds from credit agreement		1,000		2,500
Payments of financing costs		~~(59)~~—		(2125)
Repayment of subordinated convertible debentures		—		(2,200)
Net cash provided by financing activities		1,000		2,475
Proceeds from sale and issuance of equity securities		—		15,083
Effect of currency exchange rate changes on cash and cash equivalents		19		(48)
Payments of equity issuance costs		—		(44)
Net increase (decrease) in cash, cash equivalents and restricted cash		(1,061)		(818)
Proceeds from institutional exercise of warrants		610		239
Cash, cash equivalents and restricted cash at beginning of period		3,007		2,985
Proceeds from credit agreement		4,500		—
Cash, cash equivalents and restricted cash at end of period	$	1,946	$	2,167
Proceeds from PPP loan		955		—
Supplemental disclosure:
Net cash provided by financing activities		6,006		15,057
Cash paid for income taxes	$	31	$	—
Effect of currency exchange rate changes on cash and cash equivalents		(66)		(9)
Net decrease in cash, cash equivalents and restricted cash		(1,078)		2,169
Cash, cash equivalents and restricted cash at beginning of period		2,985		5,548
Cash, cash equivalents and restricted cash at end of period	$	1,907	$	7,717
Noncash investing and financing activities:
Relative fair value of warrants classified as debt issuance costs	$	1,393	$	—
Fair value of warrants included as a component of loss on extinguishment of debt	$	2,974	$	—
Fair value of warrants included as a component of loss on extinguishment of debt		2,899		—
Relative fair value of warrants classified as debt issuance costs		—		1,393
Capital expenditures accruals		~~193~~141		—
Conversion of common stock to convertible preferred stock		—		(1)

See accompanying notes to Condensed Consolidated Financial Statements.

Table of Contents

ReShape Lifesciences Inc.

Notes to Condensed Consolidated Financial Statements

(dollars in thousands, except per share amounts; unaudited)

(1) Basis of Presentation

The accompanying interim condensed consolidated financial statements and related disclosures of Reshape Lifesciences Inc. (the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020, filed on ~~April~~March 3011, ~~2020~~2021. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted.

In the opinion of management, the interim consolidated condensed financial statements reflect all adjustments considered necessary for a fair statement of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Reverse Stock Splits

During the year ended December 31, 2019, the Company’s board of directors and stockholders approved the following reverse stock split:

● 1-for-120 reverse split of the Company’s outstanding common stock that became effective after the close of market on November 11, 2019. In addition, the Company’s certificate of incorporation was amended to change the common stock and preferred stock par value from $0.01 per share to $0.001 per share. The reverse stock split in 2019 did not change the number of common or preferred shares authorized by the Company’s certificate of incorporation. All par value, share and per-share amounts have been retroactively adjusted to reflect the reverse stock split for all periods presented.

Fair Value of Financial Instruments

The carrying amounts of cash equivalents, accounts receivable, accounts payable and certain accrued and other liabilities approximate fair value due to their short-term maturities. Refer to Note 5 regarding the fair value of debt instruments and Note 8 regarding fair value measurements and inputs of warrants.

Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:


	~~September~~March 3031,
	~~2020~~2021	~~2019~~2020
Stock options	4640	~~155~~46
Convertible preferred stock	1,288	1,288
Warrants	914,483,446	138,~~647~~342,~~740~~428

Recent Accounting Pronouncements

New accounting standards adopted by the Company in ~~2020~~2021 are discussed below or in the related notes, where appropriate.

In ~~August~~December ~~2018~~2019, the ~~Financial~~FASB ~~Accounting~~issued ~~Standards~~authoritative ~~Board~~guidance ~~(“FASB”)~~intended ~~issued~~to ~~Accounting~~simplify ~~Standards~~the ~~Update~~accounting ~~(“ASU”)~~for ~~No.~~income ~~2018~~taxes: ASU 2019-1312, ~~Fair~~Income ~~Value~~Taxes ~~Measurement~~ (Topic ~~820~~740): –Simplifying ~~Disclosure~~the ~~Framework~~Accounting –for ~~Changes~~Income Taxes. This guidance eliminates certain exceptions to the ~~Disclosure~~general approach to the income tax accounting model and adds new guidance to reduce the complexity in accounting for income taxes. The adoption of this guidance on January 1, 2021 did not have a material impact on the Company’s consolidated financial statements.

Table of Contents

Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements and is intended to improve the effectiveness of disclosures, including the consideration of costs and benefits. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The adoption of this guidance did not have a material impact on the Company’s financial statements.

New accounting standards not yet adopted are discussed below.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. In May 2019, the FASB issued ASU No. 2019-05, which amended the new standard by providing targeted transition relief. The new guidance replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. In November 2019, the FASB issued ASU No. 2019-11, which amended the new standard by providing additional clarification. This guidance is effective for the fiscal years and interim periods within those years beginning after December 15, 2022. The Company is currently evaluating the impact the guidance will have on its consolidated financial statements.

Table of Contents

credit losses. In November 2019, the FASB issued ASU No. 2019-11, which amended the new standard by providing additional clarification. This guidance is effective for the fiscal years and interim periods within those years beginning after December 15, 2022. The Company is currently evaluating the impact the guidance will have on its consolidated financial statements.

(2) Liquidity and Management’s Plans

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company currently does not generate revenue sufficient to offset operating costs and anticipates such shortfalls to continue in the short-term. The Company’s history of operating losses and limited cash resources and lack of certainty regarding obtaining significant third-party reimbursement of its products, raise substantial doubt about its ability to continue as a going concern.

As of ~~September~~March 3031, ~~2020~~2021, the Company had net negative working capital of approximately $613.14 million. The Company’s principal source of liquidity as of ~~September~~March 3031, ~~2020~~2021 consisted of approximately $1.9 million of cash and cash equivalents and restricted cash, and $3.04 million of accounts receivable. During January 2021, the Company entered into a $15.0 million Line of Credit with an institutional investor, which has not been drawn upon as of March 31, 2021. For further details see Note 5.

The Company’s anticipated operations include plans to (i) ~~continue~~manufacture, toand ~~integrate~~promote the sales and operations of the ~~Company with the Lap~~LAP-~~Band~~BAND® product line in order to expand sales domestically and internationally as well as to obtain cost savings synergies, (ii) introduce to the market place reshapecareTM, (iii) continue ~~development~~clinical testing of the ReShape Vest, (~~iii~~iv) continue development of the Diabetes Bloc-Stim Neuromodulation, (v) seek opportunities to leverage ~~the~~our ~~Company’s~~ intellectual property portfolio and custom development services to provide third-party sales and licensing opportunities, and (ivvi) explore and capitalize on synergistic opportunities to ~~expand~~expend our portfolio and offer future minimally invasive treatments and therapies in the obesity continuum of care, which includes the pending merger with Obalon Therapeutics, Inc. pursuant to the merger agreement that was entered into with Obalon on January 19, 2021, for further details see Note 13. The Company believes that it has the flexibility to manage the growth of its expenditures and operations depending on the amount of available cash flows, which could include reducing expenditures for marketing, clinical and product development activities. However, the Company will ultimately need to achieve sufficient revenues from product sales and obtain additional ~~equity~~debt or ~~debt~~equity financing to support its operations.

Management is currently pursuing various funding options, including seeking additional equity or debt financing as well as a strategic merger or other transaction to obtain additional funding to support the expansion of Lap-Band product sales and to continue the development of, and to successfully commercialize, the ReShape Vest. While the acquisition of the Lap-Band product line does provide incremental revenues and cash flows to the Company, total expenses, including the cost to support the clinical trials of the ReShape Vest, are expected to exceed internally generated cash flows for the foreseeable future. While there can be no assurance that the Company will be successful in its efforts, the Company has a long history of raising equity financing to fund its development activities. Should the Company be unable to obtain adequate financing in the near term, the Company’s business, result of operations, liquidity and financial condition would be materially and negatively affected, and the Company would be unable to continue as a

Table of Contents

going concern. Additionally, there can be no assurance that, assuming the Company is able to strengthen its cash position, it will achieve sufficient revenue or profitable operations to continue as a going concern.

COVID-19 Risk and Uncertainties and CARES Act

Additionally, on January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally and on March 13, 2020, the United States declared a national emergency with respect to the coronavirus outbreak. This outbreak has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel. These mandated business closures have at times included the cessation of non-elective surgeries in Australia, Europe and the United States for all but emergency procedures. As a result of these mandates, on April 16, 2020, the Company implemented various short-term cost reductions and cash flow improvement actions, such as reducing the compensation for executives, management and key employees and decreasing operating expenses where possible. In addition, the Company ~~also~~ identified temporary headcount reductions and made the decision to furlough a portion of its workforce. During the second quarter of 2020, the mandated closures began to ease in many areas throughout the world and within the United States. As a result of this, elective surgeries started back up again through various parts of the world, which led to improved sales progressing through the third quarter. Even after the COVID-19 outbreak has subsided, the Company may continue to experience materially adverse impact on its financial condition and results of operation. Additionally, on June 15, 2020, the Company ended the temporary pay reductions and the furloughed employees returned to work. The full impact of the COVID-19 outbreak continues to evolve and it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce and has taken actions to mitigate the impact including among other things, temporary reductions in pay, and furloughs of certain positions along with deferrals in payment for cash preservation. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not ~~able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2020.~~

On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act established the Paycheck Protection Program (“PPP”) under which the Company received a PPP loan described in more detail in Note 5 below. We continue to examine the impact that the CARES Act may have on our business and the PPP loan.9

Table of Contents

able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2021.

On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act established the Paycheck Protection Program (“PPP”) under which the Company received a PPP loan described in more detail in Note 8 below. On February 3, 2021, the Company submitted the application for PPP loan forgiveness according to the terms and conditions of the SBA’s Loan Forgiveness Application (Revised June 24, 2002). On March 1, 2021, the Company received confirmation from the SBA that, the PPP Loan had been forgiven in full including all interest incurred. For further details, see Note 5.

(3) Supplemental Balance Sheet Information

Components of selected captions in the condensed consolidated balance sheets consisted of the following:

Inventory:


	~~September~~March 3031,		December 31,
	~~2020~~2021		~~2019~~2020
Raw materials	$	~~137~~214	$	—174
Sub-assemblies		~~827~~749		—733
Finished goods		1,~~024~~132		1,~~317~~337
Total inventory	$	12,~~988~~095	$	12,~~317~~244

Table of Contents

Prepaid expenses and other current assets:


	~~September~~March 3031,		December 31,
	~~2020~~2021		~~2019~~2020
Prepaid contract research organization expenses	$	580	$	1,356
Prepaid insurance	$	381	$	619
Prepaid insurance		431		190
Prepaid contract research organization expenses		214		295
Other		~~293~~241		~~165~~159
Total prepaid expenses and other current assets	$	~~1,304~~836	$	1,~~711~~073

Accrued and other liabilities:


	~~September~~March 3031,		December 31,
	~~2020~~2021		~~2019~~2020
Accrued professional services	$	599	$	1,432
Payroll and benefits	$	2,106	$	1,735
Payroll and benefits		1,526		1,021
Accrued professional services		556		446
Taxes		200		373
Customer deposits		397		398
Equity transaction related liability		—		211
Taxes		358		265
Customer deposits		357		202
Accrued insurance premium		287		272
Accrued insurance premium		—		87
Other		313		514
Other		575		495
Total accrued and other liabilities	$	4,017	$	3,630
Total accrued and other liabilities	$	3,257	$	3,821

(4) Intangible Assets

Indefinite-lived intangible assets consist of in-process research and development (“IPR&D”) for the ReShape Vest recorded in connection with the Company’s acquisition of BarioSurg, Inc. The Company’s finite-lived intangible assets consists of developed technology, trademarks and tradenames, and covenant not compete. The estimated useful lives of these finite-lived intangible assets ranges from 3 to 10 ~~years. The amortization expenses for both the three months ended September 30, 2020 and 2019 was $0.4 million, and for both the nine months ended September 30, 2020 and 2019 was $1.2 million.~~

During the second quarter of 2020, the Company performed a qualitative impairment analysis of the IPR&D and finite-lived intangible assets and did not identify any impairment as a result of this analysis.

Impairment of Intangible Assets – Second Quarter 2019

The Company has completed the feasibility study for the ReShape Vest and began clinical trials in Europe in 2018. During the second quarter of 2019, the Company performed a qualitative impairment analysis of the IPR&D. Due to delays in the clinical trials experienced during the first six months of 2019, the Company revised its expectations of when revenues would commence for the ReShape Vest, thus reducing the projected near-term future net cash flows related to the ReShape Vest. As a result, the Company performed a quantitative impairment analysis of the IPR&D and recorded a one-time nonrecurring impairment charge of $6.6 million, for the excess of the carrying value over the estimated fair value. The fair value of the IPR&D was estimated using an income approach using Level 3 assumptions which included discounting the revised projected future net cash flows to their present value, with a discount rate of 22.4%. The Company also assessed the recoverability of finite-lived intangible assets and did not identify any impairment as a result the performance of this analysis.

Table of Contents

Indefinite-lived intangible assets consist of in-process research and development (“IPR&D”) for the ReShape Vest recorded in connection with the Company’s acquisition of BarioSurg, Inc. The Company’s finite-lived intangible assets consists of developed technology, trademarks and tradenames, and covenant not compete. The estimated useful lives of these finite-lived intangible assets ranges from 3 to 10 years. The amortization expenses for both the three months ended March 31, 2021 and 2020 was $0.4 million.

(5) Debt


	~~September~~March 3031,		December 31,
	~~2020~~2021		~~2019~~2020
Asset purchase consideration	$	42,~~813~~902	$	42,~~637~~867
Credit agreement		410,500		—9,500
PPP Loan		~~955~~—		—955
Total debt		1013,~~268~~402		413,~~637~~322
Less: unamortized debt discount		~~506~~134		—545
Less: current portion of debt		613,~~558~~268		13,~~909~~609
Debt, noncurrent portion	$	~~3,204~~—	$	29,~~728~~168

Credit Facility

On January 19, 2021, the Company entered into a $15.0 million Line of Credit with an institutional investor that the Company may access from time to time until December 31, 2022. As of March 31, 2021, the Company has not drawn down any amounts under the Credit Facility. Any advances would bear interest at a rate per annum equal to the LIBOR rate plus 2.5% and would be subject to the Guarantee and Collateral Agreement between the Company and the institutional investor dated March 25, 2020.

CARES Act

On April 24, 2020, the Company entered into a PPP Loan agreement with Silicon Valley Bank (“SVB”) under the PPP, which is part of the CARES Act administered by the United States Small Business Administration (“SBA”). As part of the application for these funds, the Company in good faith, has certified that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. This certification further requires the Company to take into account our current business activity and our ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. Under this program, the Company received proceeds of $1.0 million from the PPP Loan. In accordance with the requirements of the PPP, the Company intends to use proceeds from the PPP Loan primarily for payroll costs, rent and utilities. The PPP Loan has a 1.00% interest rate per annum, matures on April 24, 2022 and is subject to the terms and conditions applicable to loans administered by the SBA under the PPP. Under the terms of PPP, all or certain amounts of the PPP Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, which the Company continues to evaluate. Further, if despite the good-faith belief that given the Company’s circumstances all eligibility requirements for the PPP Loan were satisfied, if it is later determined the Company had violated any applicable laws or regulations or it is otherwise determined the Company was ineligible to receive the PPP Loan, it may be required to repay the PPP Loan in its entirety and/or be subject to additional penalties.

~~The~~On February 23, 2021, the Company ~~continues~~submitted tothe ~~examine~~application for PPP loan forgiveness, in accordance with the ~~impact~~terms ~~that~~and conditions of the ~~CARES~~SBA’s ~~Act~~Loan ~~may~~Forgiveness ~~have~~Application on(revised ~~its~~June ~~business~~24, 2020). ~~Currently~~On March 1, 2021, the Company isreceived ~~unable~~confirmation tofrom ~~determine~~ the ~~impact~~SBA that the ~~CARES~~PPP ~~Act~~Loan ~~will~~was ~~have~~forgiven onin ~~its~~full ~~financial~~including ~~condition~~all interest incurred, ~~results~~which resulted in a gain on debt extinguishment of ~~operation~~$1.0 ormillion, ~~liquidity~~during the three months ended March 31, 2021.

Under the provisions of the CARES Act, the Company is eligible for a refundable employee retention credit subject to certain criteria. The Company recognized a $0.3 million employee retention credit during the three months ended March 31, 2021.

Credit Agreement

On March 25, 2020, the Company executed a credit agreement up to $3.5 million, with an institutional investor (the “Lender”), who holds warrants in connection with the June 2019 and September 2019 transactions. On the day of closing, the Company received $2.5 million and the additional $1.0 million may be drawn from time to time 30 days after the closing date but prior to five months after the closing date, in $500 thousand increments per draw. On June 23, ~~2020, the Company made the first additional draw of $500 thousand and on July 29, 2020 the second $500 thousand draw was made.~~

On September 14, 2020, the Company and the Lender entered into an amendment to the credit agreement that increased the amount available under delayed draw term loans by $2.0 million. The Company borrowed $1.0 million of the available amount immediately and the remaining $1.0 million will be available in increments of least $500 thousand with at least 30 days between borrowings and issued an additional 1,200,000 Series G Warrants. The Company evaluated the accounting related to the amendment and in conjunction with the warrants issued. Based on this analysis the Company determined the agreements are substantially different and extinguished the original credit agreement and recorded the amended credit agreement as a new debt at a fair value of $3.9 million. As a result, the Company recorded a debt discount of approximately $0.6 million and a $2.4 million loss on extinguishment of debt which is comprised of the fair value of the warrants and unamortized debt issuance cost with the original credit agreement, offset by the debt discount. At September 30, 2020 there was approximately $0.5 million of unamortized debt discount. Pursuant to the amendment of the credit agreement, the maturity date of the loans are March 31, 2021 and the loans bear interest at LIBOR plus 2.5%. 11

Table of Contents

2020, the Company made the first additional draw of $500 thousand and on July 29, 2020 the second $500 thousand draw was made. As required by the terms of this credit agreement, the lender exercised its warrants to purchase an aggregate of 5,085,834 shares of common stock with a current exercise price of $0.12 per warrant on April 15, 2020, in which the Company received net proceeds of $0.6 million. In addition, the Company issued to the lender 1,200,000 Series G warrants to purchase an aggregate of 1,200,000 shares of common stock. As an inducement to the Lender to enter into the amendment and make the additional loans contemplated thereby, the Company issued to the Lender an additional 1,200,000 Series G warrants dated September 14, 2020 to purchase an aggregate of 1,200,000 shares of common stock. The original Series G warrants were valued using the relative fair value basis and the amount was recorded as part of the debt issuance costs, see Note 8 for additional details.

On September 14, 2020, the Company and the Lender entered into an amendment to the credit agreement that increased the amount available under delayed draw term loans by $2.0 million. The Company borrowed $1.0 million of the available amount immediately and the remaining $1.0 million will be available in increments of least $500 thousand with at least 30 days between borrowings and issued an additional 1,200,000 Series G Warrants. The Company evaluated the accounting related to the amendment and in conjunction with the warrants issued. Based on this analysis the Company determined the agreements are substantially different and extinguished the original credit agreement and recorded the amended credit agreement as a new debt at a fair value of $3.9 million. As a result in 2020, the Company recorded a debt discount of approximately $0.6 million and a $2.4 million loss on extinguishment of debt which is comprised of the fair value of the warrants and unamortized debt issuance cost with the original credit agreement, offset by the debt discount. Pursuant to the amendment of the credit agreement, the maturity date of the loans was March 31, 2021 and the loans bear interest at LIBOR plus 2.5%.

On December 16, 2020, the Company and the Lender entered into the third amendment to the credit agreement that increased the amount available under delayed draw term loans by an additional $4.0 million. The Company borrowed the entire $4.0 million of the available amount immediately and issued an additional 4,000,000 Series G Warrants. The Company evaluated the accounting related to the amendment and in conjunction with the warrants issued. Based on this analysis the Company determined the agreements are substantially different and extinguished the original credit agreement and recorded the amended credit agreement as a new debt at a fair value of $8.9 million. As a result in 2020, the Company recorded a debt discount of approximately $0.6 million and a $5.3 million loss on extinguishment of debt which is comprised of the fair value of the warrants and unamortized debt discount cost with the original credit agreement, offset by the debt discount related to the new debt. At December 31, 2020 there was approximately $0.5 million of unamortized debt discount. Pursuant to the amendment of the credit agreement, the maturity date of the loan was March 31, 2021 and the loans bear interest at LIBOR plus 2.5%.

On January 19, 2021, the Company and the Lender entered into an amendment to the credit agreement that increased the amount available under delayed draw term loans by $1.0 million, which was used to fund the $1.0 million escrow fund securing the termination fee under the Merger Agreement and issued an additional 1,000,000 Series G Warrants. The Company evaluated the accounting related to the amendment and in conjunction with the warrants issued. Based on this analysis the Company determined the agreements are substantially different and extinguished the original credit agreement and recorded the amended credit agreement as a new debt at a fair value of $10.0 million. As a result, during the three months ended March 31, 2021, the Company recorded a debt discount of approximately $0.5 million and a $3.0 million loss on extinguishment of debt, which is comprised of the fair value of the warrants and unamortized debt issuance cost with the original credit agreement, offset by the debt discount. At March 31, 2021, there was approximately $0.1 million of unamortized debt discount. Pursuant to the amendment of the credit agreement, the maturity date of the loans are March 31, 2021 and the loans bear interest at LIBOR plus 2.5%.

On March 10, 2021, the Company and the Lender entered into an amendment to the credit agreement that extended the maturity date from March 31, 2021 to March 31, 2022. The Company has accounted for this amendment as a debt modification. The associated unamortized debt discount on the January 19, 2021 amendment of $0.1 million, will be amortized as interest expense over the term of the amended credit agreement.

Asset Purchase Consideration Payable

The asset purchase consideration payable related to the Company’s December 2018 acquisition of the Lap-Band product line from Apollo Endosurgery, Inc. (“Apollo”), was initially recorded at net present value using a discount rate of 5.1%. The asset purchase consideration payable was originally secured by a first security interest in substantially all of the Company’s assets, but that security interest terminated in accordance with its terms in October 2019. At ~~September~~March 3031, 2020, the aggregate carrying value of the current and noncurrent asset purchase consideration payable of approximately $4.8 million, as adjusted for accretion of interest of approximately $0.5 million.

~~Convertible Subordinated Debentures~~12

OnTable ~~March 29, 2019, the Company completed a private placement with certain healthcare focused institutional investors for the sale~~ of secured subordinated original issue discount convertible debentures (“debentures”) for a purchase price of $2.0 million. The debentures had a maturity of June 28, 2019 and a face amount of $2.2 million, reflecting a 10% original issue discount. The Company recorded an additional debt discount and a derivative liability for the fair value of the bifurcated embedded conversion features discussed below. The initial carrying amount of the debentures, net of discounts and deferred financing costs, was approximately $1.5 million. The Company repaid the debentures on June 20, 2019 at their face amount of $2.2 million.Contents

~~The~~2021, ~~Company analyzed~~ the ~~conversion~~aggregate ~~features~~carrying ~~embedded in the debentures and determined that bifurcation and liability classification was required under ASC 815 due to the variable number of shares issuable upon conversion. The fair~~ value of the ~~bifurcated~~current ~~embedded~~asset ~~conversion~~purchase ~~features~~consideration ~~was~~payable ~~determined~~of toapproximately be $02.59 million, as of the issuance date using a Monte Carlo model and primarily Level 3 inputs using a risk-free rate of 2.19%; probability of conversion of 98.0%; probability of repayment at each conversion of 2.0%; volatility of 161.74%; option-adjusted ~~spread of 50.0%; and a discount~~ for ~~lack~~accretion ~~or marketability~~ of ~~20.0%.~~interest ~~Upon the closing~~ of ~~the~~approximately Company’s equity financing and the Company’s planned use of a portion of the proceeds to repay the debentures, the fair value of the embedded derivative liability was reduced to zero as the conversion feature was no longer available. As the Company did not elect the fair value option for the debentures, the initial carrying amount of the debentures, net of discounts and deferred financing costs of $10.56 million~~, which was accreted to the face amount over the term to maturity~~.

In connection with the financing, the Company amended the exercise price of warrants to purchase up to 8,000,000 shares of common stock held by the investors that were issued on November 28, 2018 from $1.50 per share to $0.01 per share. The value attributable to the exercise price reduction of $0.1 million was recorded in Warrant Expense and was estimated using the Black Scholes option pricing model using a risk-free rate of 2.2%, an expected term of 4.7 years, expected dividends of zero and expected volatility of 204.4%.

(6) Leases

The Company has a noncancelable operating lease for office and warehouse space in San Clemente, California and noncancelable operating leases for certain office equipment that expire at various dates through 2022. The Company does not have any short-term leases or financing lease arrangements and the effects of any lease modifications have not been material. Certain of the Company’s equipment leases include variable lease payments that are adjusted periodically based on actual usage. Lease and non-lease components are accounted for separately.

Operating lease costs was $0.1 million for both the three months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019, and $0~~2022.~~2 million~~ ~~and $0.4 million for the nine months ended September 30, 2020 and 2019, respectively.~~ Variable lease costs were not material.

Table of Contents

Supplemental information related to operating leases is as follows:


Balance Sheet Information at September 30, 2020
Balance Sheet Information at March 31, 2021
Operating lease ROU assets	$	~~540~~390

Operating lease liabilities, current portion	$	~~309~~320
Operating lease liabilities, long-term portion		~~243~~82
Total operating lease liabilities	$	~~552~~402

Cash Flow Information for the Nine Months Ended September 30, 2020
Cash Flow Information for the Three Months Ended March 31, 2021
Cash paid for amounts included in the measurement of operating leases liabilities	$	~~242~~81

Maturities of operating lease liabilities were as follows:


Twelve months ending September 30,
Twelve months ending March 31,
2021	$	330
2022	$	333
2022		248
2023		83
2023		—
2024		—
Total lease payments		~~578~~416
Less: imputed interest		2614
Total lease liabilities	$	~~552~~402

Weighted-average remaining lease term at end of period (in years)		1.72
Weighted-average discount rate at end of period		5.1	%

(7) Equity

December 2020 Exercise of Warrants for Common Stock

On December 3, 2020, the Company issued 290,000 shares of common stock to two healthcare focused institutional investors, totaling 580,000 shares of common stock, as an exercise of pre-funded warrants issued in connection with the June 2019 and September 2019 private placement transactions. The Company received approximately $0.1 million in connection with these exercises.

Table of Contents

June 2020 Cashless Exercise of Warrants for Common Stock

On June 23, 2020, the Company issued 58,981 shares of common stock as a cashless exercise of warrants issued to the placement agents in connection with the June 2019 private placement with healthcare focused institutional investors.

May 2020 Common Stock Issued for Professional Services

On May 28, 2020, the Company issued 50,000 shares of common stock, having an aggregate fair value of $0.2 million for ongoing professional services. The $0.2 million was recorded as a prepaid asset and will be amortized over the minimum life of the agreement.

April 2020 Exercise of Warrants for Common Stock

As discussed in Note 5 above, in connection with the credit agreement, the lender exercised its Series C and Series F warrants to purchase an aggregate of 5,085,834 shares of common stock with a current exercise price of $0.12 per warrant on April 15, 2020, in which the Company received net proceeds of $0.6 million.

June 2019 Issuance of Common Stock and Warrants

On June 18, 2019, the Company completed a private placement with certain healthcare focused institutional investors for the sale of 130,000 shares of common stock at a purchase price of $2.40 per share and Series C pre-funded warrants to purchase 3,203,334 shares of common stock at a purchase price of $2.28 per share. The exercise price of each pre-funded warrant is $0.12 per share. The Company also issued Series A warrants to purchase 3,333,334 shares of common stock at an exercise price of $2.64 per share and Series B warrants to purchase 3,333,334 shares of common stock at an exercise price of $2.40 per share. Net proceeds from the private placement were $6.9 million after deducting

Table of Contents

placement agent fees and other transaction costs. In connection with the registered direct offering, the placement agent received warrants to purchase 233,334 shares of common stock at an exercise price of $3.00 per share.

February 2019 Conversion of Common Stock into New Series of Convertible Preferred Stock

On February 1, 2019, pursuant to an exchange agreement with Sabby Volatility Warrant Master Fund, Ltd. (“Sabby”) 9,993 shares of the Company’s common stock were exchanged for an aggregate of 1,192,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”), were issued in a noncash transaction. Each share of Series E Preferred Stock was convertible into one share of common stock at Sabby’s election pre-effect of the reverse stock split that occurred during November 2019. In April 2019, all shares of Series E Preferred Stock were converted into an equal number of shares of common stock. The November 2019 reverse stock split had no effect on this transaction.

Conversion of Series B Convertible Preferred Stock into Common Stock

During the nine months ended September 30, 2019, 156 shares of Series B Convertible Preferred Stock (“Series B Preferred Stock”) were converted into 1,040 shares of common stock. At September 30, 2020, the remaining 3 shares of Series B Preferred stock are convertible into 1,250 shares of common stock.

(8) Warrants

On ~~September~~January 1419, ~~2020~~2021, the Company issued 1,~~200~~000,000 Series G Warrants to an institutional investor in connection with an amendment to the credit agreement. The Series G Warrants were valued at $23.90 million using the fair value approach at the time of issuance and was recorded as a component of the loss on extinguishment of debt during the three months ended March 31, 2021, see Note 5 above for details. The fair value of the Series G Warrants was determined using a Black Scholes option pricing model using a risk- free ~~interest~~ rate of 0.2745%, an expected term of five years; expected dividends of zero and expected volatility of ~~101~~97.1%.

On ~~March~~December 2516, 2020, the Company issued 14,~~200~~000,000 Series G Warrants to an institutional investor in connection with ~~the~~an ~~credit~~amendment ~~agreement,~~to ~~see~~the ~~Note~~credit ~~5 above for details~~agreement. The Series G Warrants were valued at $15.46 million using the ~~relative~~ fair value approach at the time of issuance and was recorded as ~~deferred~~a component of the loss on extinguishment of debt ~~issuance~~in ~~cost~~2020, see Note 5 above for details. The ~~relative~~ fair value of the Series G Warrants was determined using a Black Scholes option pricing model using a risk- free ~~interest~~ rate of 0.5637%;, an expected term of five years; expected dividends of zero and expected volatility of 97100.008%.

On September 2314, ~~2019~~2020, the Company ~~entered into a warrant exercise agreement with the holders of Series B warrants~~ issued ~~in the June 2019 private placement. The holders agreed to early exercise 3~~1,~~333~~200,~~334~~000 Series BG ~~warrants~~Warrants into ~~the~~an ~~private~~institutional ~~placement~~investor in ~~exchange~~connection ~~for~~with ~~69,167~~an ~~shares~~amendment ofto ~~common stock and 3,264,167 common stock equivalents in~~ the ~~form~~credit ~~of Series F prefunded warrants~~agreement. The ~~net proceeds from the early exercise of~~ Series BG ~~warrants~~Warrants were ~~approximately~~valued at $62.9 million, ~~after~~using ~~deducting~~the ~~placement~~fair ~~agent~~value ~~fees~~approach ~~and~~at ~~other transaction costs. As an incentive for~~ the ~~warrant~~time ~~holders~~of toissuance ~~exercise~~and ~~their~~was ~~Series~~recorded Bas ~~warrant~~a incomponent ~~full,~~of the ~~warrant~~loss ~~holders~~on ~~were~~extinguishment ~~issued~~of ~~new~~debt ~~five-year~~in ~~series~~2020, Esee ~~warrants~~Note to5 ~~purchase~~above upfor todetails. ~~3,333,334~~The ~~unregistered~~fair ~~shares~~value of the ~~Company’s~~Series ~~common~~G ~~stock,~~Warrants inwas ~~aggregate,~~determined atusing ana ~~exercise~~Black ~~price~~Scholes ofoption ~~$6.00~~pricing ~~per~~model ~~share,~~using ~~through~~ a ~~private~~risk-free ~~placement.~~interest Inrate ~~connection~~of ~~with the registered direct offering~~0.27%, ~~the~~an ~~placement~~expected ~~agent~~term ~~received~~of ~~warrants~~five toyears; ~~purchase~~expected ~~233,334~~dividends ~~shares~~ of ~~common~~zero ~~stock~~and atexpected anvolatility ~~exercise price~~ of $6101.~~00 per share~~1%.

16On March 25, 2020, the Company issued 1,200,000 Series G Warrants to an institutional investor in connection with the credit agreement, see Note 5 above for details. The Series G Warrants were valued at $1.4 million using the relative fair value approach at the time of issuance and was recorded as deferred debt issuance cost in 2020. The relative fair value of the Series G Warrants was determined using a Black Scholes option pricing model using a risk-free interest rate of 0.56%; an expected term of five years; expected dividends of zero and expected volatility of 97.00%.

Table of Contents

(9) Revenue Disaggregation and Operating Segments

The Company conducts operations worldwide and has sales in the following regions: United States, Australia, Europe and Rest of World. For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020, the Company primarily only sold the LAP-BAND ~~products~~product line. The following table presents the Company’s revenue disaggregated by geography:

Three Months Ended

~~Nine Months Ended~~

~~September~~March 3031,

~~September 30,~~

~~2020~~2021

~~2019~~2020

~~2020~~

~~2019~~

United States

2,~~594~~520

31,~~143~~954

~~6,006~~

~~10,219~~

Australia

~~307~~293

~~372~~298

~~725~~

~~820~~

Europe

~~637~~379

—537

~~1,273~~

—

Rest of world

6429

—

Total net revenue

3,~~602~~221

32,~~515~~789

~~8,092~~

~~11,039~~

*The next largest individual country outside the United States was ~~United~~Australia ~~Kingdom~~ for the three months ended ~~September 30,~~March ~~2020 which was 9.6% of total revenues~~31, 2021 and ~~Australia for the nine months ended September 30,~~ 2020 which was 9.01% ~~of total revenues. Australia was the next largest individual country outside the United States for both the three~~ and ~~nine months ended September 30, 2019 and was~~ 10.~~5% and~~ 7.2%, respectively, of total revenues.

Operating Segments

The Company’s ~~operating~~conducts ~~segments~~operations ~~currently~~worldwide ~~consist~~and ofis managed in the ~~Lap-Band~~following ~~segment~~geographical regions: United States, Australia, Europe and the ~~ReShape~~Rest ~~Vest~~of ~~segment.~~World ~~These~~(primarily ~~two~~in ~~operating~~The ~~segments~~Middle ~~are~~East). ~~reported~~All ~~based~~regions onsell the ~~financial~~LAP-BAND ~~information~~product ~~provided~~line, towhich ~~the~~consisted ~~Chief~~of ~~Operating~~nearly ~~Decision~~all ~~Maker~~our (revenue and gross profit for the ~~Chief~~three ~~Executive~~months ~~Officer~~ended March 31, or2021 ~~“CODM”)~~and 2020. ~~The~~During ~~Company’s~~the ~~CODM~~second ~~evaluates~~half ~~segment~~of ~~performance~~2020 ~~based~~the onCompany ~~gross~~launched ~~profit~~reshapecare, which ~~currently~~had ~~only~~minimal ~~consists~~revenue offor ~~LAP-BAND~~the three months ended March 31, 2021 and no revenue for the three months ended March 31, 2020. The Company’s ~~CODM~~anticipates ~~does~~generating ~~not~~more ~~use~~reshapecare ~~operating~~revenue ~~segment~~late ~~assets~~in ~~information~~the tosecond ~~allocate~~quarter ~~resources~~and orin to ~~assess~~the ~~performance~~second half of the ~~operating~~year. ~~segments~~There was no revenue or gross profit recorded for the ReShape Vest or Diabetes Bloc-Stim Neuromodulation for the three months ended March 31, 2021 and ~~thus~~2020 ~~total~~as ~~segment~~these ~~assets~~two ~~have~~products ~~not~~are ~~been~~still ~~disclosed~~in the development stage.

(10) Income Taxes

The Company’s tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items arising in that quarter. In each quarter the Company updates its estimate of the annual effective tax rate. The Company’s quarter tax provision, and quarterly estimate of annual effective tax rate, are subject to significant volatility due to several factors, including the Company’s ability to accurately predict pre-tax income and loss. During the three ~~and nine~~ months ended ~~September~~March 3031, ~~2020~~2021, a $3925 thousand ~~and $108 thousand, respectively,~~ tax ~~benefit~~expense was recorded, primarily due to ~~adjusted~~projected ~~pre-tax~~ income in Australia. Noand ~~income~~Netherlands. ~~tax~~During ~~expense or benefit was recorded for~~ the three months ended ~~September~~March 3031, ~~2019~~2020, ~~due~~an to$18 ~~the~~thousand ~~valuation of allowance on deferred~~ tax ~~assets. The Company recorded an income tax~~ benefit ofwas ~~$0.6 million for the nine months ended September 30~~recorded, ~~2019,~~due into ~~connection with~~ the ~~impairment~~valuation ofallowance ~~IPR&D,~~on ~~which resulted in a reduction in the~~ deferred tax ~~liability associated with the indefinite-lived intangible asset~~assets.

In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Based on the level of historical losses, projections of losses in future periods and potential limitations pursuant to changes in ownership under Internal Revenue Code (“IRC”) Section 382, the Company provided a valuation allowance at both ~~September~~March 3031, ~~2020~~2021 and December 31, ~~2019~~2020.

1715

Table of Contents

(11) Stock-based Compensation

Stock-based compensation expense related to stock options issued under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan (the “Plan”) and as inducement grants for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020 ~~was~~were as follows:


	Three Months Ended				~~Nine Months Ended~~
	~~September~~March 3031,				~~September 30,~~
	~~2020~~2021		~~2019~~2020		~~2020~~		~~2019~~
Sales and marketing	$	—	$	(78)	$	—	$	70
General and administrative	$	101	$	427
General and administrative		255		(420)		1,029		43
Total stock-based compensation expense	$	101	$	427
Research and development		—		1		—		1,373
Total stock-based compensation expense	$	255	$	(497)	$	1,029	$	1,486

As of ~~September~~March 3031, ~~2020~~2021, there was approximately $0.51 million of total unrecognized compensation costs related to unvested stock option awards, which are to be recognized over a weighted-average period of 10.49 years. There were no stock options granted during both the three ~~and nine~~ months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020.

(12) Commitments and Contingencies

Litigation

The Company is not currently a party to any material litigation and the Company is not aware of any pending or threatened litigation against it that could have a material adverse effect on the Company’s business, operating results or financial condition. The medical device industry in which the Company operates is characterized by frequent claims and litigations, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, the Company may be involved in various legal proceedings from time to time.

Product Liability Claims

The Company is exposed to product liability claims that are inherent in the testing, production, marketing and sale of medical devices. Management believes any losses that may occur from these matters are adequately covered by insurance, and the ultimate outcome of these matters will not have a material effect on the Company’s financial position or results of operations. The Company is not currently a party to any product liability litigation and is not aware of any pending or threatened product liability litigation that is reasonably possible to have a material adverse effect on the Company’s business, operating results or financial condition.

(13) Subsequent Events and Merger

AsOn ~~part~~January of19, 2021, the ~~amendment~~Company toentered ~~the~~into ~~credit~~an agreement ~~discussed~~and inplan ~~Note~~of 5merger ~~above~~with Obalon Therapeutics, ~~the~~Inc., ~~Company~~a isDelaware ~~permitted~~corporation to(“Obalon”) ~~make~~and ~~two~~Optimus ~~additional~~Merger ~~delayed~~Sub, ~~drawdowns~~Inc., Ona ~~November~~Delaware ~~13,~~corporation ~~2020~~and wholly-owned subsidiary of Obalon (“Merger Sub”), pursuant to which Merger Sub will merge with and into ReShape as the ~~Company~~surviving ~~received~~corporation and a wholly-owned subsidiary of Obalon (the ~~first~~“Merger”). ~~additional~~As ~~draw~~a result of ~~$500 thousand~~the ~~dollars~~Merger, Obalon will be renamed “ReShape Lifesciences Inc.”

18Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, each outstanding share of ReShape common stock and series B convertible preferred stock will be converted into the right to receive shares of common stock of Obalon (“Obalon Shares”) based on the exchange ratio set forth in the Merger Agreement. Upon completion of the Merger, ReShape stockholders will own approximately 51% of the combined company’s outstanding common stock and Obalon stockholders will own approximately 49%, subject to the terms of the Merger Agreement. Obalon will, at the effective time of the Merger, assume the outstanding warrants and series C convertible preferred stock of ReShape, subject to the terms of the Merger Agreement. All outstanding stock options of ReShape will be cancelled and terminated at the effective time of the Merger without any right to receive any consideration. No fractional shares will be issued in connection with the Merger and Obalon will pay cash in lieu of any such fractional shares. The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.

Table of Contents

Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of ReShape and Obalon and the NASDAQ Stock Market’s approval of (i) the Listing of Additional Shares Notice covering the Obalon Shares to be issued in the Merger and (ii) the continued listing of the combined company following completion of the Merger ((i) and (ii) together, the “NASDAQ Approvals”). Pursuant to the Merger Agreement, ReShape has agreed to exercise its reasonable best efforts to take all necessary steps to obtain the NASDAQ Approvals following the execution of the Merger Agreement, which may include procuring additional equity or debt investments, financings or other capital raising efforts. The Merger Agreement contains specified termination rights for both ReShape and Obalon. If Obalon terminates the Merger Agreement as a result of ReShape’s breach of its covenant to use its reasonable best efforts to obtain the NASDAQ Approvals, or if either party terminates the Merger Agreement because the NASDAQ Approvals have not been obtained within 30 days following the later of the Obalon Stockholders’ Meeting and the ReShape Stockholders’ Meeting, then ReShape will be required to pay Obalon a $1.0 million termination fee, which has been deposited with a third-party escrow agent.

At the effective time of the Merger, the Board of Directors of the combined company is expected to consist of the five current members of the Board of Directors of ReShape, and the executive officers of the combined company will be the current executive officers of ReShape

In addition, under the terms of the Merger Agreement, Obalon has agreed to file with NASDAQ a Listing of Additional Shares Notice covering the Obalon shares to be issued in connection with the Merger on the NASDAQ Stock Market and to seek approval of NASDAQ to change its name to ReShape Lifesciences Inc. and its trading symbol for its shares of common stock to “RSLS” upon the effective time of the Merger.

The Merger Agreement contains customary representations, warranties and covenants by ReShape and Obalon. ReShape and Obalon have agreed, among other things, subject to certain exceptions, not to (1) directly or indirectly initiate, seek, or solicit, or knowingly encourage or facilitate any offer or alternative proposal for specified alternative transactions, or (2) participate or engage in discussions or negotiations regarding such an offer or proposal with, or furnish any nonpublic information regarding such an offer or proposal to, any person that has made or, to ReShape’s or Obalon’s knowledge, is considering making such an offer or proposal, (3) terminate, amend, modify, or waive any standstill or similar obligation (subject to certain conditions), or (4) enter into any agreement with respect to an alternative proposal. In addition, certain covenants require each of the parties to use, subject to the terms and conditions of the Merger Agreement, their commercially reasonable efforts to cause the Merger to be consummated as promptly as practicable. Subject to certain exceptions, the Merger Agreement also requires each of ReShape and Obalon to call and hold stockholders’ meetings and requires the board of directors of each of ReShape and Obalon to recommend approval of the Merger.

On April 13, 2021, the Company filed with the SEC the Definitive Proxy Statement regarding the merger proposal with Obalon. The Company held a Special Stockholders Meeting on May 13, 2021, in which the shareholders of the Company approved the merger. Obalon concurrently held a Special stockholders Meeting on May 13, 2021. To achieve a quorum for Obalon’s Special Meeting, a majority of voting power must be present or represented by proxy and as of May 13, 2021, approximately 45.5% of such shares were present or represented and approximately 96% had voted in for of the proposals. In the absence of quorum and votes necessary to approve the proposals in connection with the Merger, Obalon adjourned the meeting until May 25, 2021 in order to solicit additional votes.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q.

Except for the historical information contained herein, the matters discussed in this "Management's Discussion and Analysis of Financial Condition and Results of Operations," are forward-looking statements that involve risks and uncertainties. In some cases, these statements may be identified by terminology such as "may," "will," "should," "expects," "could," "intends," "might," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of such terms and other comparable terminology. These statements involve known and unknown risks and uncertainties that may cause our results, level of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Factors that may cause or contribute to such differences include, among others, those discussed in the "Risk Factors" section included in Item 1A of our Annual Report on Form 10-K filed on ~~April~~March 3011, ~~2020~~2021.

Except as may be required by law, we undertake no obligation to update any forward-looking statement to reflect events after the date of this report.

Overview

We are athe ~~developer~~premier ofglobal ~~minimally~~weight-loss ~~invasive~~solutions ~~medical~~company, ~~devices~~offering ~~that~~an ~~advance~~integrated ~~bariatric~~portfolio ~~surgery~~of toproven products and services that manage and treat obesity and associated metabolic ~~diseases~~disease. Our primary operations are in the following geographical areas: United States, Australia and certain European and Middle Eastern countries. Our current portfolio includes the LAP-BAND® Adjustable Gastric Banding System, ~~and~~reshapecare virtual health coaching program, the ReShape ~~VestTM,~~Vest an investigational device, to help treat more patients with obesity, and the Diabetes Bloc-Stim Neuromodulation device, a technology under development as a new treatment for type 2 diabetes mellitus. There has been no revenue recorded for the ReShape Vest asor the ~~product~~Diabetes isBloc-Stim Neuromodulation as these products are still in the development stage.

Recent Developments

On January 3019, ~~2020~~2021, ~~WHO~~the ~~announced~~Company aentered ~~global~~into ~~health~~an ~~emergency~~Agreement ~~because~~and ofPlan ~~a new strain~~ of ~~coronavirus~~Merger ~~and~~ (the ~~risks~~“Merger toAgreement”) ~~the~~with ~~international~~Obalon ~~community~~Therapeutics, ~~as the virus spreads globally beyond its points of origin~~Inc. ~~In March 2020~~, ~~the~~a ~~WHO~~Delaware ~~classified~~corporation ~~the COVID-19 outbreak as a pandemic~~(“Obalon”), ~~based on the rapid increase in exposure globally~~ and onOptimus ~~March~~Merger 13Sub, ~~2020~~Inc., ~~the~~a ~~United~~Delaware ~~States~~corporation ~~declared~~and a ~~national~~wholly-owned ~~emergency~~subsidiary ~~with~~of ~~respect~~Obalon to(“Merger ~~the~~Sub”), ~~coronavirus~~pursuant ~~outbreak. In response~~ to ~~the~~which ~~COVID-19~~Merger ~~pandemic,~~Sub onwill ~~March~~merge ~~27,~~with ~~2020,~~and ~~President Trump signed~~ into ~~law the CARES Act~~ReShape, ~~which~~with ~~provides~~ReShape ~~for~~as the ~~PPP.~~surviving ~~The~~corporation ~~Company~~and ~~received~~ a ~~PPP~~wholly-owned ~~Loan~~subsidiary of ~~$1.0~~Obalon ~~million~~(the ~~dollars~~“Merger”). ~~See~~As ~~Note~~a 2result ~~and~~of ~~Note~~the 5Merger, toObalon ~~the~~will ~~condensed~~be ~~consolidated~~renamed ~~financial~~“ReShape ~~statements~~Lifesciences Inc.”

On ~~March~~January 2519, ~~2020~~2021, concurrently with the ~~Company~~execution ~~executed~~of the Merger Agreement, ReShape entered into a ~~credit~~Credit ~~agreement~~Facility Agreement (“Credit Facility Agreement”) with anArmistice, ~~institutional~~which ~~investor~~is ReShape’s existing secured lender and majority stockholder, pursuant to ~~borrow~~which upArmistice agreed to provide ReShape with a $315.5 0 million, line of ~~which~~credit ~~$2.5~~that ~~million~~ReShape ~~was~~may ~~received~~access upfrom ~~front~~time ~~and~~to ontime ~~June~~until ~~23,~~December ~~2020~~31, ~~the~~2022. ~~Company~~ReShape ~~received~~has ~~the~~not ~~first~~drawn ~~draw~~ down ofany ~~$500~~amounts ~~thousand~~under the Credit Facility Agreement. ~~See~~Any ~~Note~~advances will bear interest at a rate per annum equal to the LIBOR rate plus 2.5%, and would be subject to the ~~condensed~~Guarantee ~~consolidated~~and ~~financial~~Collateral ~~statements~~Agreement between ReShape and Armistice dated March 25, 2020.

On ~~April~~January 1619, ~~2020~~2021, the Company ~~implemented~~entered ~~various~~into ~~short-term~~the ~~cost~~fourth ~~reductions~~amendment ~~and~~to ~~cash flow improvement actions, such as reducing~~ the ~~compensation~~credit ~~for~~agreement ~~executives,~~that ~~management~~increased ~~and key employees and decreasing operating expenses where possible. In addition,~~ the ~~Company~~amount ~~also~~available ~~identified~~under ~~temporary headcount reductions and made~~ the ~~decision~~delayed todraw ~~furlough~~term aloans ~~portion~~by ~~of its workforce~~$1.0 ~~During~~million, ~~the second quarter~~ of ~~2020,~~which ~~certain~~all ~~government-mandated~~funds ~~closures~~were ~~began~~received toupfront ~~ease~~ and ~~many~~used ~~areas~~for ~~throughout~~ the ~~world~~escrow ~~and~~fund ~~within~~securing the ~~United~~termination ~~States~~fee ~~began~~under tothe ~~allow~~Merger ~~elective surgeries~~Agreement. AsThe amaturity ~~result~~date of the ~~easing,~~loans ~~the~~under ~~Company did see sales volumes improve as we progressed through~~ the ~~third~~credit ~~quarter. Even after the COVID-19 outbreak has subsided~~agreement, weincluding ~~may~~those ~~continue~~under tothe ~~experience~~amendment ~~materially~~was ~~adverse~~March ~~impact on our financial condition and results of operations. Additionally~~31, ~~on June 15, 2020, the Company ended the temporary pay reductions and the furloughed employees returned to work~~2021.

On ~~September~~March 141, ~~2020~~2021, the Company ~~entered~~received ~~into~~confirmation anfrom ~~amendment to~~ the ~~credit~~SBA ~~agreement~~ that ~~increased~~ the ~~amount~~PPP ~~available~~Loan ~~under delayed draw term loans by $2.0 million, of which $1.0 million~~ was ~~received~~forgiven ~~upfront. In addition, to the increase~~ in ~~the~~full ~~amount available under delayed draw term loans, the maturity date of the loans under the credit agreement,~~ including ~~those~~all ~~under~~interest ~~the amendment, was extended from September 24, 2020 to March 31, 2021~~incurred. ~~See Note 5 to the condensed consolidated financial statements for further details.~~

19On March 10, 2021, the Company entered into the fifth amendment to the credit agreement that extended the maturity date from March 31, 2021 to March 31, 2022.

Table of Contents

~~During~~On April 13, 2021, the ~~third~~Company ~~quarter~~filed ofwith ~~2020~~the SEC the Definitive Proxy Statement regarding the merger proposal with Obalon. The Company held a Special Stockholders Meeting on May 13, 2021, in which the shareholders of the Company ~~launched~~approved ~~ReShapeCareTM~~the merger. ~~ReShapeCare~~Obalon isconcurrently anheld ~~effective~~a Special stockholders Meeting on May 13, ~~convenient~~2021. ~~telehealth~~To ~~based~~achieve ~~coaching~~a ~~program~~quorum ~~and~~for isObalon’s ~~typically~~Special ~~covered~~Meeting, bya ~~insurance~~majority ~~providers.~~of Itvoting ~~works~~power inmust ~~partnership~~be ~~with~~present ~~patients~~or represented by proxy and ~~doctors,~~as ~~helping~~of ~~patients~~May ~~treat~~13, ~~manage~~2021, approximately 45.5% of such shares were present or represented and ~~improve~~approximately ~~the~~96% ~~chronic,~~had ~~metabolic~~voted ~~disease~~in for of ~~obesity~~the ~~through~~proposals. aIn ~~customizable~~the ~~program~~absence ~~utilizing~~of ~~board~~quorum ~~certified~~and ~~clinical~~votes ~~health~~necessary ~~coaches~~to approve the proposals in connection with the ~~direction~~Merger, ofObalon ~~their~~adjourned ~~physician.~~the meeting until May 25, 2021 in order to solicit additional votes.

Results of Operations

The following table sets forth certain data from our unaudited consolidated statements of operations expressed as percentages of net revenue (in thousands):


	Three Months Ended ~~September~~March 3031,								~~Nine Months Ended September 30,~~
	~~2020~~2021				~~2019~~2020				~~2020~~				~~2019~~
Revenue	$	3,~~602~~221	100.0	%	$	32,~~515~~789	100.0	%	$	~~8,092~~	~~100.0~~	%	$	~~11,039~~	~~100.0~~	%
Cost of goods sold		~~1,321~~937	3629.71	%		1,~~413~~285	4046.21	%		~~3,471~~	~~42.9~~	%		~~3,849~~	~~34.9~~	%
Gross profit		2,~~281~~284	6370.39	%		21,~~102~~504	5953.89	%		~~4,621~~	~~57.1~~	%		~~7,190~~	~~65.1~~	%
Operating expenses:
Sales and marketing		1,~~160~~250	3238.28	%		~~950~~1,454	2752.01	%		~~3,446~~	~~42.6~~	%		~~3,338~~	~~30.2~~	%
General and administrative		2,~~434~~720	6784.64	%		42,~~412~~836	~~125~~101.57	%		~~7,809~~	~~96.5~~	%		~~14,237~~	~~129.0~~	%
Research and development		~~859~~571	2317.87	%		~~858~~1,295	2446.4	%		~~2,619~~	~~32.4~~	%		~~2,874~~	~~26.0~~	%
Impairment of intangible assets		—	—	%		—	—	%		—	—	%		6,588	59.7	%
Total operating expenses		4,541	141.0	%		5,585	200.3	%
Loss on litigation settlement		—	—	%		1,500	42.7	%		—	—	%		1,500	13.6	%
Operating loss		(2,257)	(70.1)	%		(4,081)	(146.3)	%
Total operating expenses		4,453	123.6	%		7,720	219.6	%		13,874	171.5	%		28,537	258.5	%
Other expense (income), net:
Operating loss		(2,172)	(60.3)	%		(5,618)	(159.8)	%		(9,253)	(114.3)	%		(21,347)	(193.4)	%
Interest expense, net		599	18.6	%		104	3.7	%
Other expense (income), net:
Loss on extinguishment of debt, net		1,960	60.9	%		—	—	%
Interest expense, net		739	20.5	%		74	2.1	%		1,632	20.2	%		390	3.5	%
Loss on foreign currency		33	1.0	%		144	5	%
Loss on extinguishment of debt		2,435	68	%		—	—	%		2,435	30	%		71	0.6	%
Loss before income tax provision		(4,849)	(150.5)	%		(4,329)	(155.2)	%
Warrant expense		—	—	%		22,564	641.9	%		—	—	%		26,821	243.0	%
Income tax expense (benefit)		25	0.8	%		(18)	(1)	%
(Gain) loss on foreign currency		(128)	(3.6)	%		(229)	(7)	%		(118)	(1.5)	%		(229)	(2)	%
Net loss	$	(4,874)	(151.3)	%	$	(4,311)	(154.6)	%
Other, net		—	—	%		727	20.7	%		—	—	%		1,336	12.1	%
Loss from continuing operations before income taxes		(5,218)	(144.9)	%		(28,754)	(818.0)	%		(13,202)	(163.1)	%		(49,736)	(450.5)	%
Income tax benefit		(39)	(1.1)	%		—	—	%		(108)	(1.3)	%		(586)	(5.3)	%
Net loss	$	(5,179)	(143.8)	%	$	(28,754)	(818.0)	%	$	(13,094)	(161.8)	%	$	(49,150)	(445.2)	%

Non-GAAP Disclosures

In addition to the financial information prepared in conformity with GAAP, we provide certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents.

Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, derivative instruments, and amortization methods, which provides a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented in the Form 10-Q have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

Adjusted EBITDA

Management uses adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, and other one-time costs.

2019

Table of Contents

~~measurement~~The ~~process.~~following ~~Adjusted~~table ~~EBITDA~~contains isa ~~defined~~reconciliation asof non-GAAP net loss ~~before~~to ~~interest,~~GAAP ~~taxes,~~net ~~depreciation~~loss ~~and~~attributable ~~amortization,~~to ~~stock-based~~common ~~compensation~~stockholders for the three months ended March 31, 2021 and ~~other~~2020 ~~one-time~~(in ~~costs.~~ thousands):

The following table contains a reconciliation of non-GAAP net loss to GAAP net loss attributable to common stockholders for the three and nine months ended September 30, 2020 and 2019 (in thousands):


	Three Months Ended March 31,
	2021		2020
GAAP net loss	$	(4,874)	$	(4,311)
Adjustments:
Interest expense, net		599		104
Income tax expense (benefit)		25		(18)
Depreciation and amortization		418		421
Stock-based compensation expense		101		427
Loss on extinguishment of debt, net		1,960		—
Non-GAAP loss	$	(1,771)	$	(3,377)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
GAAP net loss attributable to common stockholders	$	(5,179)	$	(28,754)	$	(13,094)	$	(49,150)
Adjustments:
Interest expense, net		739		74		1,632		390
Income tax benefit		(39)		—		(108)		(586)
Depreciation and amortization		419		423		1,257		1,286
Stock-based compensation expense		255		(497)		1,029		1,486
Loss on extinguishment of debt		2,435		—		2,435		71
Warrant expense		—		22,564		—		26,821
Loss on litigation settlement		—		1,500				1,500
Impairment of intangible assets		—		—		—		6,588
Other, net		—		727		—		1,336
Non-GAAP loss	$	(1,370)	$	(3,963)	$	(6,849)	$	(10,258)

Comparison of Results of Operations

Three months ended ~~September~~March 3031, ~~2020~~2021 and ~~September~~March 3031, ~~2019~~2020

Net Revenue: The following table summarizes our unaudited net revenue by geographic location based on the location of customers for the three months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020, as well as the percentage of each location to total revenue and the amount of change and percentage of change (dollars in thousands):


	Three Months Ended ~~September~~March 3031,								Amount		Percentage
	~~2020~~2021				~~2019~~2020				Change		Change
United States	$	2,~~594~~520	7278.02	%	$	31,~~143~~954	8970.41	%	$	~~(549)~~566	~~(17~~29.5)0	%
Australia		~~307~~293	89.51	%		~~372~~298	10.67	%		(655)	(171.57)	%
Europe		~~637~~379	1711.78	%		—537	—19	%		~~637~~(158)	~~100~~(29.04)	%
Rest of World		6429	10.89	%		—-	—	%		6429	100.0	%
Total net revenue	$	3,~~602~~221	100.0	%	$	32,~~515~~789	100.0	%	$	87432	215.5	%

Revenue totaled $3.62 million for the three months ended ~~September~~March 3031, ~~2020~~2021, compared to $32.58 million for the same period in ~~2019~~2020. The primary reason for the increase in revenue of $0.14 million, or 215.5%, is due to ~~increased~~a ~~sales in Europe~~$0.6 ~~Sales~~million increase in ~~Europe~~sales ~~increased~~for bythe ~~100%~~United States, asoffset ~~there~~by ~~was~~a ~~limited~~$0.2 ~~distribution~~million indecrease ~~Europe~~internationally. ~~during~~Although the ~~third~~COVID ~~quarter~~19 ofpandemic ~~2019~~restrictions began to lessen for elective surgeries domestically, ~~and~~there ~~such~~were ~~was~~still ~~included~~several ~~within~~regions ~~United~~that ~~States’~~were ~~revenue~~heavily effected internationally.

Cost of Goods Sold and Gross Profit: The following table summarizes our unaudited cost of revenue and gross profit for the three months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020, as well as the percentage compared to total revenue and amount of change and percentage of change (dollars in thousands):


	Three Months Ended ~~September~~March 3031,								Amount		Percentage
	~~2020~~2021				~~2019~~2020				Change		Change
Revenue	$	3,~~602~~221	100.0	%	$	32,~~515~~789	100.0	%	$	87432	215.5	%
Cost of goods sold		~~1,321~~937	3629.71	%		1,~~413~~285	4046.21	%		(92348)	(627.51)	%
Gross profit	$	2,~~281~~284	6370.39	%	$	21,~~102~~504	5953.89	%	$	~~179~~780	851.59	%

21Gross Profit. Gross profit for the three months ended March 31, 2021 was $2.3 million compared to $1.5 million for the same period in 2020, an increase of $0.8 million. Gross profit as a percentage of total revenue for the three months ended March 31, 2021 was 70.9% compared to 53.9% for the same period in 2020. The increase in gross profit margin is primarily due to increased volume, as revenue increased 15.5%, lower overhead department expenses, and improved product mix with higher domestic sales, which have a higher gross profit margin than international sales.

Table of Contents

Gross Profit. Gross profit for the three months ended September 30, 2020 was $2.3 million compared to $2.1 million for the same period in 2019, an increase of $0.2 million. Gross profit as a percentage of total revenue for the three months ended September 30, 2020 was 63.3% compared to 59.8% for the same period in 2019. The increase in gross profit margin is primarily due to increased average selling prices and reduced period expenses, including lower overhead department expenses.

Operating Expenses: The following table summarizes our unaudited operating expenses for the three months ended September 30, 2020 and 2019, as well as the percentage of total revenue and the amount of change and percentage of change (dollars in thousands):


	Three Months Ended September 30,								Amount		Percentage
	2020				2019				Change		Change
Sales and marketing	$	1,160	32.2	%	$	950	27.0	%	$	210	22.1	%
General and administrative		2,434	67.6	%		4,412	125.5	%		(1,978)	(44.8)	%
Research and development		859	23.8	%		858	24.4	%		1	0.1	%
Loss on litigation settlement		—	—	%		1,500	42.7	%		(1,500)	(100.0)	%
Total operating expenses	$	4,453	123.6	%	$	7,720	219.6	%	$	(3,267)	(42.3)	%

Sales and Marketing Expense. Sales and marketing expenses for the three months ended September 30, 2020 increased by $0.2 million or 22.1%, to $1.2 million, compared to $1.0 million for the same period in 2019. The increase is primarily due to an increase in payroll related expenses of $0.1 million, global sales commissions of $0.1 million and stock-based compensation expense of $0.1 million compared to the third quarter of 2019. This is offset by a reduction of approximately $0.1 million in travel and entertainment expenses, due to reduced travel from the COVID-19 pandemic.20

General and Administrative Expense. General and administrative expenses were $2.4 million for the three months ended September 30, 2020 as compared to $4.4 million for the same period in 2019, a decrease of $2.0 million, or 44.8%. The decrease is primarily due to decreases in audit, consulting and other professional service provider expense of $1.2 million, legal fees of $1.2 million and bad debt expense of $0.2 million; offset by an increase in stock-based compensation expense of $0.7 million, due to forfeitures and cancellations of options during the third quarter of 2019.

Research and Development Expense. Research and development expenses were $0.9 million for both the three months ended September 30, 2020 and 2019. The Company did have a decrease in research and development expenses due to a slowdown in the clinical trials for the ReShape Vest as a result of the COVID-19 pandemic. This was offset by an increase in payroll related expenses.

Loss on Litigation Settlement. During the third quarter of 2019, the Company recognized a contingent loss of $1.5 million relating to the patent infringement claim with Fulfillium. Under the Settlement Agreement, Fulfillium agreed to dismiss with prejudice the previously-disclosed lawsuits filed by Fulfillium.

Warrant Expense. There was no warrant expense for the three months ended September 30, 2020. Warrant expense for the three months ended September 30, 2019 includes approximately $17.2 million for issuance of the prefunded Series F Warrants and Series E Warrants. Additionally, there was approximately $5.4 million of additional expense for the increase in fair value of the warrant liability during the period.

Net Interest Expense. Net interest expense for the three months ended September 30, 2020 was $0.7 million compared to $0.1 million for the same period in 2019. The primary reason for the increase is $0.6 million is due to the amortization of deferred issuance costs and debt discount recorded as interest expense, related to the credit agreement with an institutional investor.

Loss on Extinguishment of Debt. Loss on extinguishment of debt for the three months ended September 30, 2020, was $2.4 million due to the extinguishment of debt, relating to the fair value of the warrants issued in connection with the credit agreement amendment and the debt discount.

Table of Contents

~~Gain~~Operating onExpenses: ~~Foreign~~The ~~Currency~~following ~~Exchange.~~table ~~Gain~~summarizes onour ~~foreign~~unaudited ~~currency~~operating ~~exchange~~expenses for the three months ended ~~September 30~~March 31, ~~2020~~2021 ~~was~~and ~~$0.1~~2020, ~~million~~as ~~compared~~well toas athe ~~$0.2~~percentage ~~million~~of ~~for~~total ~~the~~revenue ~~same~~and ~~period in~~ the ~~prior~~amount ~~year,~~of ~~primarily~~change ~~due~~and topercentage ~~exchange~~of ~~rate~~change ~~fluctuations~~(dollars ~~between~~in ~~the~~thousands): ~~United States dollar and Euro and Australian dollar.~~

Other, net. There were no other, net expenses for the three months ended September 30, 2020. Other, net expenses of $0.7 million for the three months ended September 30, 2019 primarily relates to transaction costs required to be expensed as a result of the liability treatment for the warrants issued in connection with our September equity financing.


	Three Months Ended March 31,								Amount		Percentage
	2021				2020				Change		Change
Sales and marketing	$	1,250	38.8	%	$	1,454	52.1	%	$	(204)	(14.0)	%
General and administrative		2,720	84.5	%		2,836	101.7	%		(116)	(4.1)	%
Research and development		571	17.7	%		1,295	46.5	%		(724)	(55.9)	%
Total operating expenses	$	4,541	141.0	%	$	5,585	200.3	%	$	(1,044)	(18.7)	%

Income Tax Benefit. An income tax benefit of $39 thousand was recorded for the three months ended September 30, 2020, primarily related to adjusted pre-tax income in Australia. There was no income tax expense or benefit for the same period in 2019.

Nine months ended September 30, 2020 and September 30, 2019

Net Revenue. The following table summarizes our unaudited net revenue by geographic location based on the location of customers for the nine months ended September 30, 2020 and 2019, as well as the percentage by location of total revenue and the amount of change and percentage of change (dollars in thousands):


	Nine Months Ended September 30,								Amount		Percentage
	2020				2019				Change		Change
United States	$	6,006	74.2	%	$	10,219	92.6	%	$	(4,213)	(41.2)	%
Australia		725	9.0	%		820	7.4	%		(95)	(11.6)	%
Europe		1,273	15.7	%		—	—	%		1,273	100.0	%
Rest of World		88	1.1	%		—	—	%		88	100.0	%
Total net revenue	$	8,092	100.0	%	$	11,039	100.0	%	$	(2,947)	(26.7)	%

~~Revenue~~Sales ~~totaled~~and $8Marketing Expense.1 ~~million~~Sales and marketing expenses for the ~~nine~~three months ended ~~September~~March 3031, ~~2020,~~2021 ~~compared~~decreased toby $~~11.~~0.2 million, ~~for~~or ~~the~~14.0%, ~~same~~to ~~period~~$1.3 inmillion, ~~2019.~~compared ~~The~~to ~~primary~~$1.5 ~~reason~~million for the ~~decrease~~same period in ~~revenue of $2~~2020.9 ~~million,~~The ordecrease ~~26.7%,~~ is mainly due to a ~~reduction~~decrease in ~~sales~~payroll ~~from~~related ~~the~~expenses ~~COVID-19~~of ~~pandemic~~$0.2 million, ~~which~~primarily ~~caused~~a ~~elective~~result ~~surgeries~~of tothe beEmployee ~~shut~~Retention ~~down~~Credit ~~throughout~~received ~~the~~as ~~world~~a atpart ~~the end~~ of the ~~first~~CARES ~~quarter~~Act, ofand ~~2020.~~a Inreduction ~~the~~in ~~second~~consulting ~~quarter~~fees of ~~2020,~~$0.1 ~~sales~~million. ~~volumes~~This ~~began~~was tooffset ~~improve~~by asan weincrease ~~progressed~~of ~~through~~$0.1 ~~the~~million ~~quarter~~in advertising and ~~continued~~marketing ~~through~~expenditures as the ~~third~~Company ~~quarter~~expects ~~with~~to ~~revenues~~focus inmore ~~the~~efforts ~~quarter~~on ~~being~~advertising ~~consistent~~and ~~with~~marketing ~~the~~for ~~prior year~~2021.

~~Cost~~General ofand ~~Goods~~Administrative ~~Sold~~Expense. General and ~~Gross~~administrative ~~Profit:~~expenses ~~The~~for ~~following~~the ~~table~~three ~~summarizes~~months ~~our~~ended ~~unaudited~~March ~~cost~~31, of2021 ~~revenue~~decreased ~~and~~by ~~gross~~$0.1 ~~profit~~million, or 4.4%, to $2.7 million, compared to $2.8 million for the ~~nine~~same ~~months~~period ~~ended~~in ~~September~~2020. ~~30,~~The ~~2020~~decrease ~~and~~is ~~2019,~~primarily asdue ~~well~~to asdecreases ~~percentage~~in stock-based compensation expense of ~~total~~$0.3 ~~revenue~~million from lack of stock option grants, $0.1 million in bad debt expense on improved collections, and $0.1 million in travel and entertainment expenses from reduced travel during the ~~amount~~COVID of19 ~~change~~pandemic. This was offset by an increase in audit, consulting, legal and ~~percentage~~professional services of ~~change~~$0.4 ~~(dollars~~million inprimarily ~~thousands):~~related to the proposed merger with Obalon.


	Nine Months Ended September 30,								Amount		Percentage
	2020				2019				Change		Change
Revenue	$	8,092	100.0	%	$	11,039	100.0	%	$	(2,947)	(26.7)	%
Cost of goods sold		3,471	42.9	%		3,849	34.9	%		(378)	(9.8)	%
Gross profit	$	4,621	57.1	%	$	7,190	65.1	%	$	(2,569)	(35.7)	%

Research and Development Expense. Research and development expenses for the three months ended March 31, 2021 decreased by $0.7 million, or 55.9%, to $0.6 million, compared to $1.3 million for the same period in 2020. The decrease is primarily a result of a slowdown in clinical trials for the ReShape Vest due to the COVID 19 pandemic.

Net Interest Expense. Net interest expense for the three months ended March 31, 2021 increased $0.5 million to $0.6 million compared to $0.1 million for the same period in 2020. The primary reason for the increase is due to the amortization of debt discount recorded as interest expense, related to the credit agreement with an institutional investor.

~~Gross~~Loss ~~Profit.~~on ~~Gross~~Extinguishment ~~profit~~of ~~for~~Debt, ~~the~~Net. ~~nine~~Loss ~~months~~on ~~ended~~extinguishment ~~September~~of 30debt, ~~2020~~net ~~was~~for ~~$4.6~~the ~~million~~three ~~compared~~months toended ~~$7.2~~March ~~million~~31 ~~for~~2021 ~~the~~was ~~same~~$2.0 ~~period in 2019~~million, awhich ~~decrease~~consisted of $23.60 million. ~~Gross~~related ~~profit~~to asthe afair ~~percentage~~value of ~~total~~the ~~revenue~~warrants ~~for~~issued ~~the~~in ~~nine~~connection ~~months~~with ~~ended~~the ~~September~~January 3019, ~~2020~~2021 ~~was~~credit ~~57.1%~~agreement ~~compared to 65~~amendments.1% ~~for~~This ~~the~~was ~~same~~offset ~~period~~by ina ~~2019~~$1.0 ~~The~~million ~~decrease~~gain inon ~~gross~~the ~~profit~~full ~~margin~~extinguishment isof ~~primarily~~our ~~due~~PPP toloan, ~~reduced~~as ~~overall~~we ~~sales~~received ~~from~~official ~~the~~confirmation ~~COVID-19~~of ~~pandemic,~~forgiveness ~~coupled~~on ~~with~~March ~~an increase in international sales~~1, ~~which have a lower margin than domestic sales~~2021.

Income Tax Expense (Benefit). An income tax expense of $25 thousand was recorded for the three months ended March 31, 2021, primarily related to projected income in Australia and Netherlands, compared to a benefit of $18 thousand for the three months ended March 31, 2020.

Table of Contents

Operating Expenses: The following table summarizes our unaudited operating expenses for the nine months ended September 30, 2020 and 2019, as well as the percentage of total revenue, and the amount of change and percentage of change (dollars in thousands):


	Nine Months Ended September 30,								Amount		Percentage
	2020				2019				Change		Change
Sales and marketing	$	3,446	42.6	%	$	3,338	30.2	%	$	108	3.2	%
General and administrative		7,809	96.5	%		14,237	129.0	%		(6,428)	(45.1)	%
Research and development		2,619	32.4	%		2,874	26.0	%		(255)	(8.9)	%
Impairment of intangible assets		—	—	%		6,588	59.7	%		(6,588)	(100.0)	%
Loss on litigation settlement		—	—	%		1,500	13.6	%		(1,500)	(100.0)	%
Total operating expenses	$	13,874	171.5	%	$	28,537	258.5	%	$	(14,663)	(51.4)	%

Sales and Marketing Expense. Sales and marketing expenses for the nine months ended September 30, 2020 increased by $0.1 million or 3%, to $3.4 million, compared to $3.3 million for the same period in 2019. The increase is primarily due an increase in global commissions of $0.2 million and consulting fees of $0.1 million, offset by a reduction in travel and entertainment expenses of $0.2 million due to a reduction of travel caused by the COVID-19 pandemic.

General and Administrative Expense. General and administrative expenses were $7.8 million for the nine months ended September 30, 2020 as compared to $14.2 million for the same period in 2019, a decrease of $6.4 million, or 45.1%. The decrease is primarily due to decreases in audit, consulting and other professional service provider expense of $3.2 million, legal fees of $2.6 million, stock-based compensation expense of $0.3 million, recruiting fees of $0.2 million and $0.1 million of bad debt expense.

Research and Development Expense. Research and development expenses were $2.6 million for the nine months ended September 30, 2020 as compared to $2.9 million for the same period in 2019. The $0.3 million, or 8.9%, decrease is primarily due to a slowdown of the clinical trials for the ReShape Vest due to the COVID-19 pandemic.

Impairment of Intangible Assets. There was no impairment charge recorded during the nine months ended September 30, 2020. During the nine months ended September 30, 2019, we recorded an impairment charge of $6.6 million on the indefinite-lived intangible asset recorded in connection with our acquisition of BarioSurg, Inc. (“BarioSurg”) in May 2017. We also assessed the recoverability of finite-lived intangible assets during the second quarter of 2019 and did not identify any impairment as a result the performance of this analysis.

Loss on Litigation Settlement. During the nine months ended September 30, 2019, the Company recognized a contingent loss of $1.5 million relating to the patent infringement claim with Fulfillium. Under the Settlement Agreement, Fulfillium agreed to dismiss with prejudice the previously-disclosed lawsuits filed by Fulfillium.

Warrant Expense. There was no warrant expense for the nine months ended September 30, 2020. Warrant expense for the nine months ended September 30, 2019 includes noncash expense of $26.8 million for the value of variable price features included with the warrants and common stock issued in connection with our equity financing completed in June 2019 and September 2019 in excess of the proceeds received and changes in fair value of the warrant liability.

Net Interest Expense. Net interest expense for the nine months ended September 30, 2020 was $1.6 million compared to $0.4 million for the same period in 2019. The primary reason for the increase of $1.2 million is due to the amortization of deferred issuance costs and debt discount recorded as interest expense, related to the credit agreement with an institutional investor, slightly offset by the interest expense related to the subordinated debentures in 2019.

Loss on extinguishment of debt. Loss on extinguishment of debt for the nine months ended September 30, 2020, was $2.4 million due to the extinguishment of debt, relating to the fair value of the warrants issued in connection with the credit agreement amendment and the debt discount. The loss on extinguishment of debt for the nine months ended September 30, 2020, was $0.1 million, relating to the early repayment of the debentures.

Table of Contents

Loss on Foreign Currency Exchange. Loss on foreign currency exchange for the nine months ended September 30, 2020 was $0.1 million compared to $0.2 million for the same period 2019, primarily due to exchange rate fluctuations between the United States dollar, Euro and Australian dollar.

Other, net. There were no other, net expenses for the nine months ended September 30, 2020. Other, net expenses of $1.3 million for the nine months ended September 30, 2019 primarily relates to transaction costs required to be expensed as a result of the liability treatment for the warrants issued in connection with our June 2019 and September equity financing.

Income Tax Benefit. An income tax benefit of $0.1 million was recorded for the nine months ended September 30, 2020, primarily related to expected losses in Australia. There was an income tax benefit of $0.6 million for the same period in 2019, related to the impairment of IPR&D.

Liquidity and Capital Resources

~~As of September 30, 2020, we had $1.9 million of cash and cash equivalents to fund operations.~~ We have financed our operations to date principally through the sale of equity securities and debt ~~financing~~financings. ~~Our~~During ~~anticipated operations include plans to (i) continue to integrate~~ the ~~sales~~three ~~and~~months ~~operations~~ended ofMarch ~~the~~31, ~~Company~~2021 ~~with the newly acquired Lap-Band product line in order to expand sales domestically~~ and ~~internationally as well as to obtain cost savings synergies~~2020, ~~(ii)~~we ~~continue~~received ~~development~~proceeds of ~~the~~$1.0 ~~ReShape~~million ~~Vest, (iii) seek opportunities to leverage our intellectual property portfolio~~ and ~~custom~~$2.5 ~~development~~million, ~~services to provide third party sales and licensing opportunities~~respectively, ~~and~~from ~~(iv)~~the ~~explore~~credit ~~and~~agreement ~~capitalize~~with onan ~~synergistic~~institutional ~~opportunities~~investor. toAs ~~expand~~of ~~our~~March ~~portfolio~~31, ~~and~~2021, ~~offer~~we ~~future~~had ~~minimally invasive treatments and therapies in the obesity continuum of care~~$1.9 ~~The~~million ~~Company believes that it has the flexibility to manage the growth~~ of ~~its~~cash ~~expenditures~~ and ~~operations~~cash ~~depending~~equivalents, onincluding ~~the~~$1.1 ~~amount~~million of ~~available~~restricted cash. ~~flows,~~During ~~which~~March ~~could~~of ~~include reducing expenditures for marketing~~2021, ~~clinical and product development activities. However,~~ the Company ~~will~~received ~~ultimately~~confirmation ~~need to achieve sufficient revenues~~ from ~~product~~the ~~sales~~SBA ~~and~~that ~~obtain~~the ~~additional~~PPP ~~debt~~Loan orwas ~~equity~~forgiven ~~financing~~in tofull ~~support~~including ~~its~~all ~~operations~~interest incurred.

~~Management~~In isJanuary ~~currently pursuing various funding options~~2021, ~~including~~we ~~seeking~~successfully ~~additional~~obtained ~~equity or debt financing as well as~~ a ~~strategic~~$15.0 ~~merger~~million orline ~~other transaction to obtain additional funding to support the expansion~~ of ~~Lap-Band~~credit ~~product~~with ~~sales~~an ~~and~~institutional ~~to continue the development of~~investor, and toentered ~~successfully~~into ~~commercialize,~~an ~~the~~agreement ~~ReShape Vest. While the acquisition of the Lap-Band product line does provide incremental revenues and cash flows~~ to ~~the~~merge ~~Company,~~with ~~the~~Obalon ~~cost~~resulting toin ~~support~~ the ~~clinical~~removal ~~trials~~ of the ~~ReShape~~going ~~Vest~~concern ~~is expected to exceed internally generated cash flows for the foreseeable future~~opinion. ~~While~~The ~~there~~Company ~~can~~anticipates bethis ~~no assurance that the Company~~ will beresult ~~successful~~ in ~~its efforts,~~ the ~~Company~~combined ~~has~~company’s acommon ~~long~~stock ~~history~~being oftraded ~~raising~~on ~~equity~~the ~~financing~~NASDAQ toCapital ~~fund its development activities~~Market. ~~Should~~Obalon ~~the~~is ~~Company~~currently betraded ~~unable~~on tothe ~~obtain~~NASDAQ ~~adequate~~Stock ~~financing~~Exchange inunder the ~~near~~ticker ~~term,~~OBLN. ~~the~~As ~~Company’s business, result~~ of ~~operations~~March 31, ~~liquidity and financial condition would be materially and negatively affected~~2021, ~~and~~ the Company ~~would~~has benot ~~unable~~made ~~to continue as~~ a ~~going~~draw ~~concern.~~on ~~Additionally,~~this ~~there~~Credit ~~can be no assurance that, assuming the Company is able to strengthen its cash position, it will achieve sufficient revenue or profitable operations to continue as a going concern~~Facility.

Table of Contents

The Company is also pursuing further funding options, including seeking additional equity or debt financing to support the expansion of the LAP-BAND product line, the introduction of reshapecare to the market place; and the continued development and successful commercialization of the ReShape Vest and the ReShape Diabetes Bloc-Stim Neuromodulation.

The following table summarizes our change in cash and cash equivalents and restricted cash (in thousands):


	~~Nine~~Three Months Ended
	~~September~~March 3031,
	~~2020~~2021		~~2019~~2020
Net cash used in operating activities	$	(61,~~788~~961)	$	(123,~~879~~245)
Net cash used in investing activates		(~~230~~119)		—
Net cash provided in financing activities		61,~~006~~000		152,~~057~~475
Effect of exchange rate changes		~~(66)~~19		(948)
Net change in cash and cash equivalents	$	(1,~~078~~061)	$	~~2,169~~(818)

Net Cash Used in Operating Activities

Net cash used in operating activities from continuing operations was $62.80 million and $123.92 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021 and ~~2019~~2020, respectively. For the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021, net cash used in operating activities was primarily the result of our net loss of $134.19 million, partially offset by non-cash adjustments for amortization of intangible assets of $0.4 million, net loss on extinguishment of debt of $2.0 million, stock-based compensation expense of $0.1 million, and amortization of debt discount of $0.5 million. In addition, we had an increase in sales that resulted in a cash inflow related to inventory of $0.2 million. We also had a positive cash effect due to prepayments made late in 2020 of $0.2 million, as well as a positive cash effect related to accounts payable and accrued liabilities of $0.3 million. This was offset by a $0.8 million negative cash effect from increased accounts receivable primarily attributable to late sales during the first quarter.

Table of Contents

for amortization of intangible assets of $1.2 million, noncash interest expense of $0.2 million, loss on extinguishment of debt of $2.4 million, stock-based compensation expense of $1.0 million, bad debt expense of $0.2 million, provision for inventory excess and obsolescence of $0.2 million and amortization of debt discount and deferred debt issuance cost of $1.4 million. In addition, the Company has focused on collection of accounts receivable, which resulted in an increase to cash of $1.0 million, which was offset by an increase in change of inventory of $0.9 million primarily due to expected inventory buildup related to our impending manufacturing transfer, and a decrease in accounts payable and accrued liabilities of $1.3 million.

Net Cash Used in Investing Activities

Net cash used in investing activities for the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021 was $0.21 million, comprised of capital expenditures related to the process of moving manufacturing from Costa Rica to the United States~~. This move is expected to be completed by the start of the first quarter 2021. Because of this~~, weand ~~anticipate~~product ~~net cash used in investing activities to be higher in 2020 compared to 2019~~development. ~~There was no cash used in investing activities for the nine months ended September 30, 2019.~~

There was no cash used in investing activities for the three months ended March 31, 2020.

Net Cash Provided by Financing Activities

Net cash provided by financing activities ofwas $61.0 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021, ~~consisted~~due ofto ~~proceeds~~$1.0 million received from the credit agreement with an institutional investor ~~of $4~~.5 million, $1.0 million received under the CARES Act in the form of a PPP Loan and $0.6 million in cash received from the exercise of warrants, offset by approximately $0.1 million of debt issuance costs.

Net cash provided by financing activities of $152.1 5 million for the ~~nine~~three months ended ~~September~~March 3031, ~~2019~~2020, ~~was~~consisted ~~primarily related to $15.1 million~~ of ~~cash~~ proceeds we received ~~in connection with an equity financing completed in June 2019 and September 2019. A portion of the net proceeds~~ from the ~~equity~~credit ~~financing~~agreement ~~were~~with ~~used to repay the $2.2 million face amount of convertible subordinated debentures that were issued at~~ an ~~original~~institutional ~~issue discount of 10% in March 2019~~investor.

Operating Capital and Capital Expenditure Requirements

Our anticipated operations include plans to (i) ~~continue to~~ integrate the sales and operations of the Company with the ~~newly~~LAPBAND ~~acquired Lap-Band~~ product line; in order to expand sales domestically and internationally as well as to obtain cost savings synergies, (ii) introduce to the market place reshapecare, (iii) continue ~~development~~clinical test of the ReShape Vest, (~~iii~~iv) continue development of the Diabetes Bloc-Stim Neuromodulation, (v) seek opportunities to leverage ~~the~~our ~~Company’s~~ intellectual property portfolio and custom development services to provide third -party sales and licensing opportunities, and (ivvi) explore and capitalize on synergistic opportunities to expand our portfolio and offer future minimally invasive treatments and therapies in the obesity continuum of care. The Company believes that it has the flexibility to manage the growth of its expenditures and operations depending on the amount of available cash flows, which could include reducing expenditures for marketing, clinical and product development activities. ~~However, the Company will ultimately need to achieve sufficient revenues from product sales and obtain additional equity or debt financing to support its operations.~~

Obtaining funds through the sale of additional equity and debt securities or the warrant holders’ exercise of outstanding common stock warrants may result in dilution to our stockholders. If we raise additional funds through the issuance of debt securities, these securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations. The sale of additional equity may require us to obtain approval from our stockholders to increase the number of shares of common stock we have authorized under our certificate of incorporation. We may require additional capital beyond our currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, if at all. If we are unable to obtain additional financing, we may be required to reduce the scope of, delay, or eliminate some or all of our planned research, development and commercialization activities, which could materially harm our business. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to products or proprietary technologies, or grant licenses on terms that are not favorable. 22

Our forecast of the period of time through which our financial resources will be adequate to support our operations, the costs to complete development of products and the cost to commercialize our products are forward-looking statements and involve risks and uncertainties, and actual results could vary materially and negatively as a result of a number of factors, including the factors discussed in Part I, Item 1A, “Risk Factors”, of our Annual Report on Form

Table of Contents

~~10-K~~Obtaining funds through the sale of additional equity and debt securities or the warrant holders’ exercise of outstanding common stock warrants may result in dilution to our stockholders. WeIf ~~have~~we ~~based~~raise additional funds through the issuance of debt securities, these ~~estimates~~securities oncould ~~assumptions~~have rights senior to those of our common stock and could contain covenants that would restrict our operations. The sale of additional equity may ~~prove~~require us to obtain approval from our stockholders to increase the number of shares of common stock we have authorized under our certificate of incorporation. We may require additional capital beyond our currently forecasted amounts. Any such required additional capital may not be ~~wrong~~available on reasonable terms, ~~and~~if at all. If we ~~could~~are ~~utilize~~unable to obtain additional financing, we may be required to reduce the scope of, delay, or eliminate some or all of, our ~~available~~planned ~~capital~~research, ~~resources~~development ~~sooner~~and ~~than~~commercialization activities, which could materially harm our business. In addition, if we ~~currently~~raise ~~expect~~additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to products or proprietary technologies, or grant licenses on terms that are not favorable.

~~The~~Our ~~Company’s~~forecast ~~acquisition~~ of the ~~Lap-Band~~period ~~product~~of ~~line~~time ~~provides~~through ~~incremental~~which ~~revenues~~our ~~and~~financial ~~cash~~resources ~~flows~~will ~~and~~be ~~does~~adequate ~~not~~to ~~require~~support ~~further~~our ~~product~~operations, ~~development.~~the Incosts ~~order~~ to ~~continue~~complete ~~the~~ development of, products and tothe ~~successfully~~cost to commercialize ~~the~~our ~~ReShape~~products ~~Vest,~~are ~~the~~forward-looking ~~Company’s~~statements ~~management~~and isinvolve ~~currently~~risks ~~pursuing~~and ~~various funding options~~uncertainties, ~~including~~and ~~seeking~~actual ~~additional~~results ~~equity~~could orvary ~~debt~~materially ~~financing~~and asnegatively ~~well~~ as a ~~strategic~~result ~~merger~~of ~~or other transaction to obtain additional funding. The Company has~~ a ~~long~~number ~~history~~ of ~~raising equity financing to fund its development activities; however~~factors, ~~there~~including ~~can be no assurance that~~ the ~~Company~~factors ~~will~~discussed ~~continue to be successful~~ in ~~its~~Part ~~efforts.~~I, ~~Should~~Item ~~the Company be unable to obtain adequate financing in the near term~~1A, ~~the~~“Risk ~~Company’s business~~Factors”, ~~results~~ of ~~operations,~~our ~~liquidity~~Annual ~~and~~Report ~~financial~~on ~~condition~~Form ~~would~~10-K. beWe ~~materially~~have ~~and~~based ~~negatively~~these ~~affected,~~estimates ~~and~~on ~~the~~assumptions ~~Company~~that ~~would~~may beprove ~~unable~~ to ~~continue as a going concern. Additionally, there can~~ be ~~no assurance that~~wrong, ~~assuming~~and ~~the~~we ~~Company~~could isutilize ~~able~~our toavailable ~~strengthen~~capital ~~its~~resources ~~cash~~sooner ~~position,~~than itwe ~~will~~currently ~~achieve sufficient revenue or profitable operations to continue as a going concern~~expect. ~~The unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.~~

Because of the numerous risks and uncertainties associated with the development of medical devices, such as our ReShape Vest and Diabetes Bloc-Stim Neuromodulation, we are unable to estimate the exact amounts of capital outlays and operating expenditures necessary to complete the development of the ReShape Vest and Diabetes Bloc-Stim Neuromodulation or other additional products and successfully deliver a commercial product to the market. Our future capital requirements will depend on many factors, including, but not limited to, the following:

●

the cost and timing of establishing sales, marketing and distribution capabilities;

● the cost of establishing clinical and commercial supplies of our ReShape Vest and Diabetes Bloc-Stim Neuromodulation, and any products that we may develop;

● the rate of market acceptance of our ReShape Vest and Diabetes Bloc-Stim Neuromodulation and any other product candidates;

●

the cost of filing and prosecuting patent applications and defending and enforcing our patent and other intellectual property rights;

●

the cost of defending, in litigation or otherwise, any claims that we infringe third-party patent or other intellectual property rights;

●

the effect of competing products and market developments;

●

the cost of explanting clinical devices;

●

the terms and timing of any collaborative, licensing or other arrangements that we may establish;

● any revenue ~~from~~generated by sales of our ~~established~~ Lap-Band, ~~product~~reshapecare, ~~any~~ReShape ~~revenue~~Vest, ~~generated~~Diabetes byBloc-Stim ~~sales~~Neuromodulation ~~of our ReShape Vest~~ or future products;

●

the scope, rate of progress, results and cost of our clinical trials and other research and development activities;

●

the cost and timing of obtaining any further required regulatory approvals; and

Table of Contents

●

the extent to which we invest in products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions.

Critical Accounting Policies and Estimates

The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and revenues and expenses during the periods reported. Actual results could differ from those estimates. Information with respect to our critical accounting policies and estimates which we believe could have the most significant effect on our reported results and require subjective or complex judgments by management is contained on pages 37-38 in Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no significant changes from the information discussed therein.

27During the three months ended March 31, 2021 there were no material changes to our significant accounting policies which are fully described in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020.

Table of Contents

and require subjective or complex judgments by management is contained on pages 37-38 in Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report on Form 10-K for the year ended December 31, 2019. There have been no significant changes from the information discussed therein.

During the three and nine months ended September 30, 2020 there were no material changes to our significant accounting policies which are fully described in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.

Off-Balance Sheet Arrangements

As of ~~September~~March 3031, ~~2020~~2021, we did not have any off-balance sheet arrangements.

Recent Accounting Pronouncements

See Note 1 to our condensed consolidated financial statements for a discussion of recent accounting pronouncements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide disclosure pursuant to this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), defines the term “disclosure controls and procedures” as those controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Based on their evaluation as of ~~September~~March 3031, ~~2020~~2021, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed at a reasonable level and effective as of the end of the period covered in the report in providing reasonable assurance that the information we are required to disclose in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting during the quarter ended ~~September 30~~March 31, ~~2020~~2021 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is not currently a party to any litigation and the Company is not aware of any pending or threatened litigation against it that reasonably likely to have a material adverse effect on the Company’s business, operating results or financial condition. The medical device industry in which the Company operates is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, the Company may be involved in various legal proceedings from time to time.

Table of Contents

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors set forth in Item 1A. “Risk Factors” of our ~~2019~~2020 Annual Report on Form 10-K filed on ~~April~~March 3011, ~~2020~~2021.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

None.

Uses of Proceeds from Sale of Registered Securities

None.

Purchases of Equity Securities

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

2925

Table of Contents

ITEM 6. EXHIBITS


Exhibit No.		Description

10.1		~~Second~~Fifth Amendment to Credit Agreement, dated ~~September~~March 1410, ~~2020~~2021, by and between the Company and Armistice Capital Master Fund Ltd. ~~(incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 15, 2020 (File No. 001-33818)).~~

10.2		Series G Common Stock Purchase Warrant, dated September 14, 2020, issued by the Company to Armistice Capital Master Fund Ltd. (incorporated by reference to exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 15, 2020 (File No. 001-33818)).

31.1**		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2**		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101**		Financial statements from the Quarterly Report on Form 10-Q of the Company for the quarter ended ~~September~~March 3031, ~~2020~~2021, formatted in Extensible Business Reporting Language: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Stockholders’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows and (v) the Notes to Condensed Consolidated Financial Statements.

**	Filed herewith.

3026

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	RESHAPE LIFESCIENCES INC.

	BY:	/S/ BARTON P. BANDY
		Barton P. Bandy
		President and Chief Executive Officer
		(principal executive officer)

	BY:	/S/ thomas stankovich
		Thomas Stankovich
		Senior Vice President and Chief Financial Officer
		(principal financial and accounting officer)

Dated: November 13, 2020
Dated: May 17, 2021

3127

Filing Compare · ReShape Weightloss Inc.